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ABSTRACT

Iyer, Lavanya K. PhD, Purdue University, December 2015. High-Resolution Mass Spectrometric
Approaches to Study Protein Structure and Environment in Lyophilized Solids. Major Professor:
Elizabeth Topp.

Proteins comprise a growing class of therapeutics that is used to treat various diseases such as
diabetes and cancer. However, intrinsic structural features such as the primary sequence and
extrinsic factors such as pH, temperature, agitation and metal ions can promote instability that
manifests as chemical degradation (e.g. oxidation, deamidation, hydrolysis) and/or physical
degradation (aggregation, phase separation). Since several degradation pathways are accelerated
by diffusion in solution, proteins are lyophilized to improve stability. The lyophilized formulation may
still undergo degradation during manufacture and/or storage. The mechanism of protein
aggregation in lyophilized solids is not well understood or predictable by conventional analytical
methods such as solid-state Fourier-transform infrared spectroscopy (ssFTIR) and differential
scanning calorimetry (DSC) and this poses challenges in rational formulation design.

This dissertation is aimed at understanding local protein structure and environment in the solid
state using high-resolution mass spectrometric methods. Chapter 2 examines protein side-chain
matrix accessibility using solid-state photolytic labeling- mass spectrometry (ssPL-MS). The use of
a photoactive probe, photo-leucine (pLeu) enabled side-chain labeling in lyophilized formulations,
reported by our group for the first time. High-resolution information at the peptide level was obtained
using bottom-up tandem mass spectrometry. Differences in labeling patterns and side-chain matrix
accessibility were observed when sucrose or guanidine hydrochloride was used as an excipient.
This work also used a photoactive probe incorporated within the amino acid sequence of a

xvi

glucagon-derived peptide to detect interactions with excipients and peptides in the solid state.
Residue-level information about the preferred site of peptide-peptide crosslinking was obtained
using tandem mass spectrometry.

Although peptide-matrix interactions could be visualized using a photoactive amino acid (PAA)
derivative within the primary sequence, incorporating an unnatural amino acid into larger proteins
is fairly difficult and may alter higher order structure by disturbing intra-protein contacts. Therefore,
a novel photo-crosslinking method was developed to further examine the solid-state environment
of lyophilized proteins, described in Chapter 3. A heterobifunctional crosslinking reagent was used
to crosslink the protein with the matrix in the solid state. Some loop regions showed increased
peptide-peptide adducts, while helix E showed more hydration compared to other regions. In the
presence of raffinose, water replacement was not detected in the solid state; instead there was
some evidence of micro-phase separation without crystallization in the solid state. Thus local
protein environment in the solid state could be probed without the need for PAA incorporation within
the protein sequence.

Lyophilization is an effective, yet expensive stabilization strategy, since conservative freeze-drying
cycles often require long hours of drying. The stochastic nature of ice nucleation and lack of control
over freezing can result in vial-to-vial heterogeneity due to differences in the degree of supercooling
and ice crystal size. The research described in Chapter 4 focuses on using a variety of analytical
methods to characterize lyophilized protein formulations to determine the effect of excipient and
freezing step on protein structure. Myoglobin in the presence or absence of sucrose was lyophilized
with or without controlled ice nucleation in a pilot-scale LyoStar freeze dryer. Ice nucleation
occurred over a range of temperatures and times with uncontrolled nucleation, while controlled ice
nucleation with rapid depressurization resulted in near-simultaneous ice nucleation. The sucrosecontaining formulation showed greater retention of protein structure by ssFTIR and solid-state
hydrogen-deuterium exchange mass spectrometry (ssHDX-MS).

Greater conformational

xvii

homogeneity was observed in the sucrose-containing formulation by ssHDX-MS peak width
analysis. No significant differences in secondary structure were detected between controlled and
uncontrolled nucleation using ssFTIR and ssHDX-MS. Myoglobin lyophilized with controlled
nucleation in the presence of sucrose showed the greatest side-chain labeling, as determined by
ssPL-MS. The results show that high-resolution mass spectrometric methods can be used to study
process- and excipient effects on protein structure.

This thesis addresses limitations in current analytical methods used to characterize protein
structure in the solid state. Whereas ssFTIR and DSC have lower sensitivity and provide
information averaged over the entire sample, mass spectrometric methods can provide peptidelevel information about conformational changes occurring in a small subpopulation of protein. Highresolution mass spectrometric methods have the potential to provide reliable and predictable
protein formulation screening and facilitate rational drug design.

1

CHAPTER 1.

1.1

INTRODUCTION

PROTEIN AGGREGATION IN THE SOLID STATE

Protein drugs are an increasingly important sector in the pharmaceutical market. In 2009, the ten
best-selling protein drugs had a combined sales value of close to $50 billion 1. The number of
protein drugs on the market is expected to rise in the next few years, given the expiration of patents
and growth of generic protein drugs or “biosimilars”. Protein instability is a major issue hampering
formulation development, especially since each protein behaves uniquely in different environments.
Formulation development for proteins is largely based on trial and error, making drug development
very expensive and time-consuming. Many proteins are lyophilized to improve formulation stability.
Although lyophilization confers greater stability on formulations compared to solution, degradation
is known to occur in the solid state and during each step of the freeze-drying process

2-4.

Protein

aggregation is a serious problem in the clinical setting because it can reduce efficacy and
compromise safety. Aggregation is also critical for the pharmaceutical industry, because it
complicates the manufacturing and formulation process. Therefore it is important to characterize
these lyophilized proteins at the conformational level to ensure integrity of protein structure,
especially for biosimilars.

Protein-side chains play an important role in the aggregation pathway. Intermolecular backbone
and side-chain interactions facilitate the formation of amorphous aggregates

5, 6.

Site-directed

mutagenesis and molecular dynamic simulation (MDS) studies on peptides have implicated
hydrophobic interactions between aromatic side-chains and electrostatic interaction through saltbridges in the formation and stabilization of amyloid fibrils

7-9.

Hence it becomes important to

characterize the side-chain environment. The aggregation pathway is not well understood for

2

proteins in solution and lyophilized formulations. It is especially difficult to follow aggregation in
amorphous solids because of the inherent structural and spatial heterogeneity. Our lack of
understanding of solid-state protein aggregation is compounded by the absence of robust, highresolution analytical methods, which makes it difficult to study protein stability at the molecular level.
Traditional analytical techniques such as Fourier-Transform Infrared Spectroscopy (FTIR), Raman
Spectroscopy and Differential Scanning Calorimetry (DSC) are semi-quantitative at best, suffer
from low sensitivity and provide low-resolution information at the global level

10-12.

Solid state

Nuclear Magnetic Resonance spectroscopy (ssNMR) can provide site-specific information about
conformational changes

13;

however it requires extensive sample preparation using isotopic

labeling and is also less sensitive to amorphous systems. Solid-state hydrogen-deuterium
exchange in combination with mass spectrometry (ssHDX-MS) is an analytical tool that allows
protein backbone environment to be probed with higher resolution. This technique has been used
previously by our group to characterize formulations based on the amount of protection against
exchange afforded by carbohydrate excipients 14.

The aim of this dissertation is to characterize lyophilized protein structure and environment with
high resolution. In our ongoing research program, we have developed two novel analytical
techniques: ssPL-MS and ssPC-MS to probe protein side-chain environment in lyophilized
formulations. These techniques have been used in molecular biology to map the interactome within
cells

15-17.

PL-MS has also been described for solution-state studies to probe protein topography

and ligand binding 18, 19, while PC-MS is typically used to map the protein-protein interaction (PPI)
interface in solutions 20, 21. To our knowledge, our research is the first application of PL-MS and PCMS to study molecular interactions in lyophilized solids. The research is significant to both industry
and patients in several ways. These two high-resolution analytical methods can potentially identify
local reactive sites participating in aggregation. Knowledge gained from these experiments can be
used to design formulations rationally, by using excipients or chaperones that block reactive sites
on the protein structure. Thus, protein aggregation can be controlled by designing an ideal solid-

3

state environment that promotes protein stability and minimizes aggregation. Our novel technique
is expected to detect aggregate-prone regions earlier than conventional analytical methods, which
is important in mitigating patient risk and improving formulations in the early stages of development.
This will also reduce the cost of formulation development and time to reach market, thus lowering
the burden of healthcare on consumers.

1.2

COVALENT LABELING OF PROTEINS

Covalent labeling of proteins refers to the modification of amino acids by reaction with side-chain
groups. The labeling agent contains a functional group that is reactive towards specific or nonspecific amino acids under certain conditions (e.g. alkaline pH or UV irradiation). Covalent labeling
combined with mass spectrometry is a useful proteomics tool. It allows the side-chain environment
to be mapped with high resolution and provides information about solvent (or matrix) accessibility
of surface amino acids to the probe. The effect of excipients on protein tertiary structure can be
determined by changes in labeling pattern. Labeling reagents may be classified as chemical or
photolytic agents.

1.2.1

Chemical Labeling Agents

These probes undergo activation over a certain pH range and form covalent bonds with amino acid
side chains in their proximity. The ratio of labeling agent to protein must be optimized to obtain a
sufficient fraction of labeled protein without significantly perturbing protein structure. Previously
used chemical agents include N-hydroxysuccinimide esters (NHS esters; amine specific), 2,3butanedione (BD; Arg specific), N-alkylmaleimides (Cys specific) and diethylpyrocarbonate (DEPC;
His, amine, hydroxyl specific). Although pH control ensures that the dominant reaction of the agent
is with its target amino acid, sometimes side-reactions may occur and reduce the yield of the
desired labeled amino acid. For example, BD is reactive towards Arg at pH 7-10; however it can
also undergo photoactivation and react with Lys and His
to be modified to minimize side-reactions.

22.

Hence, reaction conditions may need
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Chemical labeling agents have been used to probe the structure of pre-aggregate species in
solution. Mendoza et al. used three complementary labeling agents (NHSA, BD and DEPC) and
examined the effect of β2 microglobulin (β2m) dimer formation on extent of amino acid modification
in solution 19. About one-third of the surface amino acids and about one-half of the amino acids in
the dimer interface were probed. The change in reactivity and extent of labeling of amino acids with
increasing dimer formation was indicative of a change in the side-chain environment. Covalent
labeling combined with molecular dynamic simulations suggested that residues with the greatest
change in modification are likely present at or near the dimer interface.

1.2.2

Photolytic Labeling Agents

These probes undergo activation of certain functional groups on exposure to UV light. Activation
leads to the formation of short-lived, unstable radicals or neutral molecules with unpaired electrons.
These species readily participate in insertion or addition reactions with neighboring molecules with
the formation of a new covalent bond. Photolytic analogs of amino acids have been synthesized to
study protein-protein interactions. These photolytic amino acids (PAAs) can be inserted into protein
and peptide sequences through mutagenesis, translational incorporation during protein expression
or solid-phase synthesis. The most common photoactive moieties in PAAs are arylazides,
diazirines and benzophenones.

1.2.2.1

Arylazides

Arylazides are activated when exposed to UV light below 310 nm, forming reactive singlet nitrenes
(lifetime ~ 1 ns) with expulsion of molecular nitrogen. Nitrenes can undergo ring expansion to form
dehydroazepines that are particularly reactive towards nucleophilic amines and form covalent
adducts. Nitrenes can also add to unsaturated bonds or insert into C-H and N-H bonds. The main
disadvantage of crosslinking proteins with arylazides is possible damage to proteins at the
activation wavelength (254 nm).
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1.2.2.2

Diazirines

Diazirine-containing PAAs such as 2-amino 4,4’ azipentanoic acid (photo-leucine, pLeu) and L-2amino-5,5-azi-hexanoic acid (photo-methionine, pMet) undergo activation at higher wavelengths
than arylazides. At 350-365 nm, the diazirine ring loses molecular nitrogen and forms an active
carbene species. The lifetime of the carbene is very short (on the order of nanoseconds) and it
undergoes insertion into any C-C and X-H bond (X= C, H, N, O, S) or addition on to a C=C bond in
its immediate molecular cage (Fig. 1.1). Thus carbenes do not show preference for any particular
amino acid and are expected to label any surface residue indiscriminately. Other reactions of
carbenes include quenching by water to form a hydroxy derivative and self-interaction to form an
alkene.

Figure 1.1. Schematic showing reactions of carbene formed upon activation of pLeu (reprinted with
permission from ‘Mass Spectrometry of Laser-Initiated Carbene Reactions for Protein Topographic
Analysis 18 Copyright (2011) ACS).
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Photolytic labeling- mass spectrometry (PL-MS) with pLeu has been reported in solution for
myoglobin (Mb) and calmodulin (CaM) using a 1:10,000 molar ratio of protein to pLeu and a pulsed
laser for irradiation 18. CaM was detected carrying up to 4 labels, while Mb showed up to 2 labels.
PL-MS was sensitive to changes in CaM conformation upon ligand binding, with ~ 39 % reduction
in labeling for the ligand-bound protein compared to free CaM.

1.2.2.3

Benzophenones

In contrast to diazirines, benzophenone-containing PAAs (e.g. p-benzoyl L-phenylalanine; pBpA)
appear to have greater affinity for electron-rich residues. Upon exposure to UV-A light, the carbonyl
group on the benzophenone is activated to a diradicaloid triplet state (with a lifetime of 80-100 μs
in the absence of an H-donor)

23.

The oxygen radical abstracts a hydrogen atom from a suitably

oriented C-H group in its vicinity and forms a ketyl radical (Fig. 1.2). The hydrogen-deficient alkyl
radical and the ketyl radical recombine to form a covalently bonded adduct. Effective H-donors
include C-H bonds in Leu and Val and CH2 groups adjacent to heteroatom containing amino acids
like Met, Arg and Lys

23.

Unlike diazirines, activation of benzophenones is reversible. The

diradicaloid species relaxes to its ground state in the absence of a suitably oriented H-donor. Thus,
adduct formation may take a long time with several excitation-relaxation cycles until a favorable
geometry is achieved.
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hν
350-365 nm

Alkyl group (H-donor)

Benzophenone PAA

H abstraction

recombination

Benzophenone
PAA - alkyl
adduct
Figure 1.2. Schematic depicting covalent bond formation between a benzophenone- containing
PAA and an amino acid on exposure to UV-A light (adapted from

1.3

23).

CROSSLINKING OF PROTEINS

Crosslinking refers to the formation of a new intramolecular or intermolecular covalent bond
between two amino acid side chains. This may be achieved by chemical and/or photolytic means.
Crosslinkers

may

contain

one

functional

group

(e.g.

1-ethyl-3-[3-dimethylaminopropyl]

carbodiimide hydrochloride; EDC), but usually are homobifunctional or heterobifunctional.
Homobifunctional crosslinkers (e.g. disuccinimidyl suberate; DSS) contain identical functional
groups at each end of a spacer arm. They must be used in a single-step reaction since they react
identically with their target group (e.g. amine to amine crosslinking), hence they are not very precise.
Heterobifunctional crosslinkers (e.g. succinimidyl 4,4’- azipentanoate, SDA) have two different
reactive groups at each end of a spacer arm and hence can be used to crosslink two specific
functional groups. Heterobifunctional agents are used in a two-step process and offer better
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precision than homobifunctional agents. Step 1 involves reaction of one end of the crosslinker with
its target side chain (e.g. amine-reactive succinimidyl ester). After the reaction is complete, the
excess unreacted crosslinker is removed by dialysis or desalting. Step 2 involves activation of the
other end of the crosslinker (e.g. sulfhydryl-reactive N-alkylmaleimide) which results in formation of
covalently linked adducts. Semi-specific labeling can be achieved by using a heterobifunctional
crosslinker with a chemically reactive functionality at one end of the spacer and a photoactive
functionality at the other end. For example, SDA contains an amine-reactive NHS-ester moiety at
one end and a non-specific diazirine ring at the other end (Fig. 1.3).

pH 7-9

Succinimidyl 4,4’azipentanoate (SDA)

Crosslinked
Adducts

hν
350-365 nm

H

NH
Protein 1

Protein 2 or
Excipient or
Water
N2
Protein 2 or
Excipient or
Water

O

Figure 1.3. Schematic illustrating mechanism of crosslinking two proteins using the
heterobifunctional photoactive crosslinker succinimidyl 4,4’- azipentanoate (SDA) (adapted from
Life Technologies https://www.lifetechnologies.com/order/catalog/product/26167).

Spacer arms are usually carbon chains, but may also include reducible disulfide bonds. The length
of the spacer arm determines steric effects and limits the number of crosslinked adducts formed.
Cross-linkers may be classified based on the length of the spacer arm. Zero-length cross-linkers
have no spacer arm and form a direct covalent bond between two molecules without themselves
participating in the crosslink. The zero-length carbodiimide crosslinkers EDC is commonly used to
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conjugate carboxyl groups and amine groups via an amide bond. In general, short spacer arms (48 Å) are better suited to study intramolecular crosslinks, while long spacer arms (~ 12 Å) favor
intermolecular crosslinks. The spacer arm may also be cleaved to facilitate separation of the
crosslinked species and reduce the complexity of MS analysis.

PAAs with a single active functionality can also be used for crosslinking. Peptides and proteins with
a PAA incorporated within the amino acid sequence can be irradiated to produce cross-linked
molecules. Kolbel et al observed differences in crosslinking patterns as a function of secondary
structure using peptides containing pLeu within the primary sequence 20. Similarly, changes in the
conformation of the receptor PPAR-α upon agonist and antagonist binding were observed using
genetically encoded pBpA incorporated within the sequence of PPAR-α

24.

In addition, PAAs

incorporated within the protein sequence using the translational machinery of cells have been used
to map the intracellular interactome 15, 25, 26.

Crosslinking with mass spectrometry can provide useful, high-resolution information about
interacting partners and binding interfaces. Gomes and Gozzo used an HPP (succinimidyl 2-[(4,4´azipentanamido)ethyl]-1,3´-dithioproprionate (SDAD) to crosslink Mb

27.

SDAD has an NHS ester

at one end and a diazirine ring at the other, separated by a 13.6 Å spacer arm with a cleavable
disulfide bond. The NHS moiety was reacted first at alkaline pH, followed by removal of excess
unreacted SDAD. The labeled protein was irradiated to activate the diazirine end, resulting in
formation of crosslinked products. The spacer arm was cleaved by reduction to facilitate analysis.
Both intra- and intermolecular crosslinks were detected by MS analysis. Furthermore, the sites of
crosslinking could be localized using MS/MS.

Although crosslinking improves resolution of side-chain environment, it also increases the
complexity of data, especially when there are multiple crosslinks within the same peptide. In order
to simplify analysis of crosslinked peptides, Schilling et al have classified modifications based on
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the type of product formed 28. Internal rearrangement or quenching of the activated labeling agent
result in Type 0 ‘deadend’ modifications. The reactive probe may also label an amino acid within
the same polypeptide chain, forming a Type 1 intrapeptide crosslink. Reaction of the label with an
amino acid belonging to another protein molecule results in a Type 2 interpeptide crosslink between
a longer peptide (α) and a shorter peptide (β). Additionally, various combinations of these
modifications are also possible, making data analysis complicated.

1.4

ADVANTAGES OF MODIFICATION USING PAAs

PAAs offer a number of advantages over chemical labeling agents. For example, since labeling is
not biased towards a particular amino acid, the entire protein surface can be probed. In addition,
small PAAs like pLeu and pMet can be incorporated into the sequence of the protein through
metabolic labeling. The PAAs simply need to be added to cell culture media instead of their wildtype counterpart, and the cells’ translational machinery will incorporate the PAA into the protein
sequence. Thus the modified proteins themselves can be used as labeling agents. Furthermore,
UV irradiation allows PAAs to be added to the reaction mixture prior to activation. It also provides
better control of reaction than chemical agents such as NHS that require pH control and quenching
of excess reagent.

1.5

ADVANTAGES OF CROSSLINKING

Thus far, indirect evidence of solid-state protein-excipient and protein-water interactions has been
reported using FTIR spectroscopic data29,

30.

These inferences are based on band areas for

carboxylate hydrogen-bonding interactions. A disadvantage of FTIR is that band resolution
depends on arbitrary deconvolution input parameters such as half-bandwidth, resulting in altered
peak position and intensity for the same spectrum. Solid-state crosslinking allows for direct
interrogation of protein-matrix interactions using mass spectrometry. High-resolution qualitative
information about the presence of protein-protein, protein-excipient and protein-water adducts in
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different formulations can be obtained. An additional advantage is lack of interference from water
vapor.

1.6

SPECIFIC AIMS

The inherent instability of proteins makes the formulation of biologics challenging. Formulation
development is often done by a trial and error approach, which can be time-consuming and
expensive. In addition, analytical methods currently used to characterize protein structure lack
sufficient resolution, making it difficult to draw meaningful conclusions about conformation. In this
research, two novel analytical methods, solid-state photolytic labeling-mass spectrometry
(ssPL-MS) and solid-state crosslinking-mass spectrometry (ssPC-MS) are being developed.
The overall objective of this research is to develop ssPL-MS and ssPC-MS as tools for rational
protein formulation, supplanting the current paradigm of trial and error. PL-MS using
photoreactive amino acid analogs (PAAs) has been described for solution samples, to study
protein-protein interaction in vitro as well as in vivo

15, 18, 20.

Similarly, PC-MS using

heterobifunctional photoactive probes (HPPs) has been used to elucidate the three-dimensional
structure and molecular interactions of proteins

27, 31, 32.

This proposal aims to adapt PL-MS and

PC-MS to the solid state (ssPL-MS and ssPC-MS) for lyophilized formulations. A photoactive
labeling or crosslinking reagent (PAA/HPP) will be used to probe the protein side chain environment
in three different ways; (a) PAA incorporated in the lyophilized formulation matrix as an excipient
and then irradiated (external labeling), (b) PAA incorporated within a protein/peptide sequence and
then lyophilized (internal labeling) and (c) Protein side-chains derivatized with HPP, lyophilized and
irradiated (crosslinking). When the PAA/HPP is irradiated with UV light (350-365 nm), the
photoreactive functional group on the probe is activated and reacts with protein molecules in its
vicinity (within a certain distance). As a result, a covalent bond is formed between the PAA/HPP
and protein side chain. The labeled/crosslinked protein is analyzed by MS at the intact level and
after enzymatic digestion.
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Labeling and crosslinking can provide direct information about the local environment of amino
acid side-chains in protein formulations. This makes the method complementary to hydrogendeuterium exchange mass spectrometry (HDX-MS), which probes secondary structure. The
location of the label can identify side-chains on the protein that are accessible to the PAA/HPP.
The three dimensional structure of a protein or protein complex can also be elucidated, since the
crosslinking reaction is constrained by distance. An added advantage is the absence of backexchange of the label, which is a limitation of HDX-MS.

SPECIFIC AIM 1. To probe protein-protein and protein-matrix interactions in lyophilized
protein formulations using external photolytic labeling and crosslinking.
In order to rationally design a lyophilized protein formulation, high-resolution, molecular-level
information about the protein and surrounding matrix is required. To obtain this information, two
approaches will be used (i) a PAA probe will be added to the excipient matrix in lyophilized
formulations and irradiated with UV-A light (365 nm) to form covalent bonds between the probe and
neighboring protein molecules. The protein-PAA adducts will be analyzed by LC-MS at the intact
protein level and at the peptide level (ii) a PAA probe will be incorporated within a peptide sequence
and lyophilized with excipients. Crosslinking will be initiated by UV irradiation and peptide-peptide
and peptide-excipient adducts will be analyzed by LC-MS at the intact protein level and at the
peptide level. The studies test the hypothesis that ssPL-MS and ssPC-MS can detect proteinprotein and protein-matrix interactions.

SPECIFIC AIM 2. To probe protein conformation, protein-protein and protein-matrix
interactions in solids and solutions using crosslinking.
The goal of Specific Aim 2 is to crosslink a model protein with matrix components in lyophilized
formulations. Complementary to Specific Aim 1, this research allows detection of protein-protein,
protein-excipient and protein-water adducts in the solid state. Myoglobin will be derivatized with a
heterobifunctional crosslinking reagent in solution and lyophilized with different excipients. The
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crosslinker will be irradiated in the solid state to produce crosslinked adducts. ESI-HPLC-MS will
be used to identify these adducts after trypsin digestion. The studies test the hypothesis that
changes in protein-protein and protein-matrix interactions can be detected with high resolution in
different lyophilized formulations using ssPC-MS.

SPECIFIC AIM 3. To study the effect of process and excipient on lyophilized protein
conformation using mass spectrometric methods.
Processing conditions can affect protein structure and result in instability during lyophilization,
storage or reconstitution. Specific Aim 3 focuses on detection of conformational changes in the
solid-state using high-resolution analytical methods. Myoglobin will be lyophilized with and without
controlled ice nucleation in a pilot-scale freeze-dryer. Product temperature will be monitored during
lyophilization and conventional product characterization techniques such as FTIR spectroscopy
and moisture content analysis will be performed. Backbone conformational changes will be
monitored using solid-state hydrogen deuterium exchange-mass spectrometry (ssHDX-MS) and
side-chain matrix accessibility will be assessed using solid-state photolytic labeling- mass
spectrometry (ssPL-MS). The hypothesis is that these high-resolution methods are more sensitive
to structural changes than conventional solid-state FTIR spectroscopy.

1.7

OVERALL APPROACH

Model Proteins and Peptides: Myoglobin will be used as a model protein for Specific Aim 1, 2
and 3, as it is a fairly small molecule with no cysteines and has also been used for ssHDX studies
in our lab previously. Hence enzymatic digestion and MS analysis will be relatively straightforward.
A glucagon-derived peptide (GDP) obtained from the N- terminus of glucagon (1-HSQGTFTS-8;
hereafter referred to as GCG (1-8)*) will be used for Specific Aim 1 for internal labeling experiments.
The PAA probe p-benzoyl-L-phenylalanine (pBpA) will replace Phe in GCG (1-8)*. This peptide
was selected because the N- and C-termini of glucagon have been implicated in aggregation33, 34.
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Photo amino acid analogs (PAAs) as probes: The PAA probes to be used are L-photo-leucine
(L-2-amino-4,4-azipentanoic acid; pLeu), L-photo-methionine (L-2-amino-5,5-azi-hexanoic acid;
pMet) ((Pierce Biotechnology, Rockford, IL) and p-benzoyl-L-phenylalanine (pBpA) (Bachem,
Torrance, CA). These PAAs have different reaction mechanisms upon exposure to UV light at 350365 nm; the diazirine functional group of pLeu and pMet forms a reactive carbene intermediate that
inserts non-specifically into any C-C and X-H bond (X= C, H, N, O, S) or adds on to a C=C bond in
its immediate molecular cage 18. Labeling with pLeu and pMet is quite promiscuous, as the carbene
intermediate does not favor a particular amino acid. On the other hand, the benzophenone group
in pBpA forms a reactive ketyl radical that reacts preferentially with C-H bonds and forms new C-C
covalent linkages 23. Besides these PAAs, an HPP succinimidyl 4,4’ azipentanoate (NHS-diazirine;
SDA) will also be used. SDA contains an N-hydroxysuccinimide (NHS) ester that reacts with
primary amines at alkaline pH to form an amide bond. It also contains a second functional group,
a photoactive diazirine ring that forms a carbene upon exposure to UV-A light and reacts with any
amino acid side-chain. The two groups are connected by a short (3.9 Å) carbon chain spacer arm.

Data analysis: In silico digestion of labeled proteins can be performed in MassHunter software as
well as others such as the FindPept tool (ExPASy). This theoretical list can be matched with the
observed masses using MassHunter. Analysis of cross-linked peptides is more challenging
because the fragment ions obtained by MS/MS are also cross-linked. This greatly increases the
complexity of the data and manual assignment of masses often must be made. The software
GPMAW can compute the mass of possible crosslinked peptides after data is provided for the
primary sequence of the crosslinked proteins, the type of crosslinker and the enzyme used for
digestion. XQuest and XLink assign m/z values to MS/MS fragment peaks and can be used to
analyze fragmentation of cross-linked or modified peptides.
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CHAPTER 2.

PHOTOLYTIC LABELING TO PROBE MOLECULAR INTERACTIONS IN
LYOPHILIZED POWDERS

This chapter was published as a research article in Molecular Pharmaceutics (2013) and can be
found online at http://pubs.acs.org/doi/abs/10.1021/mp4004332

2.1

ABSTRACT

Local side-chain interactions in lyophilized protein formulations were mapped using solid-state
photolytic labeling-mass spectrometry (ssPL-MS). Photoactive amino acid analogs (PAAs) were
used as probes and either added to the lyophilized matrix or incorporated within the amino acid
sequence of a peptide. In the first approach, apomyoglobin was lyophilized with sucrose and
varying concentrations of photo-leucine (L-2-amino-4, 4’-azipentanoic acid; pLeu). The lyophilized
solid was irradiated at 365 nm to initiate photolabeling. The rate and extent of labeling were
measured using ESI-HPLC-MS, with labeling reaching a plateau at ~ 30 min, forming up to 6
labeled populations. Bottom-up MS/MS analysis was able to provide peptide-level resolution of the
location of pLeu. ssPL-MS was also able to detect differences in side-chain environment between
sucrose and guanidine hydrochloride formulations. In the second approach, peptide GCG (1-8)*
containing p-benzoyl-L-phenylalanine (pBpA) in the amino acid sequence was lyophilized with
various excipients and irradiated. Peptide-peptide and peptide-excipient adducts were detected
using MS. Top-down MS/MS on the peptide dimer provided amino acid-level resolution regarding
interactions and the cross-linking partner for pBpA in the solid state. The results show that ssPLMS can provide high-resolution information about protein interactions in the lyophilized
environment.
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2.2

INTRODUCTION

Protein drugs are an increasingly important part of the global pharmaceuticals market. In 2009, the
ten best-selling protein drugs had a combined sales value of close to $50 billion1. The number of
approved protein drugs is expected to increase in the next few years, particularly given the
expiration of patents and the growth of biosimilars. According to a report by Global Industry
Analysts, Inc., biosimilars are expected to be valued at $17.9 million by 20172. However the
inherent instability of proteins and their tendency to aggregate is an obstacle to the development
of these life-saving medicines. In an attempt to maintain stability and provide adequate shelf life,
many proteins are lyophilized. In addition to those products marketed as lyophilized powders, the
protein itself may be lyophilized for storage prior to final formulation in either solution or solid forms.
Although lyophilized formulations usually confer greater stability when compared to solution,
degradation may still occur in the solid state and during the freeze-drying process3-6. Retention of
native protein structure in the lyophilized solid has generally been associated with improved stability
during shelf-storage and a decreased propensity for aggregate formation7-9. Ensuring the retention
of native conformation would benefit from analytical methods that could identify subtle protein
structural perturbations in lyophilized solids with high resolution. Such information could be used to
design formulations rationally and to screen candidate formulations efficiently.

Most of the current analytical techniques used to characterize proteins in the solid state lack
sufficient resolution to serve as design tools, however. Methods such as Fourier transform-infrared
spectroscopy (FTIR), Raman spectroscopy and differential scanning calorimetry (DSC) have been
used to study structural changes in lyophilized proteins10-13. These methods are semi-quantitative
at best, suffer from low sensitivity and can provide only low-resolution information on protein
structure. Solid-state nuclear magnetic resonance spectroscopy (ssNMR) can provide site-specific
information about conformational changes14,

15,

but requires extensive sample preparation and

isotopic labeling, and is less sensitive in amorphous samples than in those that are crystalline.
Thus, ssNMR is not always useful for lyophilized protein formulations, which are usually amorphous.
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Recently, our group has developed solid-state hydrogen-deuterium exchange with mass
spectrometric analysis (ssHDX-MS) to allow the protein environment in amorphous solids to be
probed with higher resolution. ssHDX-MS provides structural information with peptide level
resolution, and has been used previously by our group to characterize protein conformations in
lyophilized solids containing various excipients16, 17.

In the work reported here, we have developed a complementary analytical technique, solid-state
photolytic labeling with mass spectrometric analysis (ssPL-MS), to probe protein structure and
matrix interactions in lyophilized formulations. In solution, PL-MS with photoreactive amino acid
analogs (PAAs) has been used to study protein/peptide conformation and protein-protein
interactions (PPIs)18-20. The approach has also been used in living cells to map the interactome2123.

In solution PL-MS, a solution containing protein and PAA is irradiated with UV light (350-365

nm), activating the PAA photoreactive functional group, which then forms a covalent bond between
the PAA and protein in its immediate vicinity. The labeled protein is analyzed by MS at the intact
protein level and by MS/MS fragmentation after enzymatic digestion (bottom-up) or direct
fragmentation (top-down). The location of the label identifies sites on the protein that are accessible
to the photoreactive probe, providing information about the side-chain environment. This makes
the method complementary to HDX-MS, which probes backbone environment and secondary
structure. Moreover, the covalently attached label is permanent and does not undergo backexchange, a limitation of HDX. Solution state PL-MS has also been carried out by incorporating the
PAA within a protein or peptide sequence19, 24. Exposure to UV light generates photoadducts of the
PAA-containing protein/peptide with interacting molecules (e.g. ligand) in the microenvironment.
These photoadducts can then be digested enzymatically and analyzed to identify the reactive sites
at the interface of the complex.

In the current work, we have adapted PL-MS for proteins in lyophilized solids. PAAs were used to
probe the side chain protein environment in two different ways: (i) by incorporating a PAA into the
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lyophilized solid as an excipient and (ii) by incorporating a PAA into the sequence of a model
peptide. In studies using a PAA probe as an excipient (i), apomyoglobin (ApoMb) was selected as
a model protein and L-photo-leucine (L-2-amino-4, 4’-azipentanoic acid; pLeu) was used as an
excipient. In studies with the PAA incorporated into the protein sequence (ii), an octapeptide
derived from the N-terminus of human glucagon (1-HSQGTFTS-8) with the phenylalanine residue
(F6) replaced by the PAA p-benzoyl-L-phenylalanine (pBpA) was used. The two PAAs have
different reaction mechanisms upon exposure to UV light. The diazirine functional group of pLeu
forms a reactive carbene intermediate that inserts non-specifically into any C-C or X-H bond (X= C,
N, O, S), or adds to a C=C bond in its immediate molecular cage. The benzophenone group in
pBpA forms a reactive ketyl radical that reacts preferentially with C-H bonds and forms new C-C
covalent linkages25, 26. The results demonstrate that photolytic labeling occurs in lyophilized solids
when the label is either incorporated into the matrix (i) or into a model peptide (ii). The results also
show that the extent of labeling varies with position in the protein sequence and with solid
composition. To our knowledge, this is the first reported use of photolytic labeling to map the protein
environment in lyophilized solids. The findings support further development of the method to probe
the amorphous solid state and in formulation development.

2.3

MATERIALS AND METHODS

Apomyoglobin (apoMb) from equine skeletal muscle, monobasic and dibasic potassium hydrogen
phosphate, L-methionine (Met), L-leucine (Leu), sucrose, trehalose, urea and guanidine
hydrochloride were purchased from Sigma Aldrich (St. Louis, MO). L-photo-leucine (L-2-amino-4,
4-azipentanoic acid; pLeu) was obtained from Thermo Scientific (Rockford, IL). An octapeptide
derived from the N-terminus of glucagon (HSQGT-pBpA-TS; henceforth referred to as GCG (1-8)*)
containing the photoreactive amino acid p-benzoyl-L-phenylalanine (pBpA) within its sequence was
synthesized by American Peptide Company (Sunnyvale, CA) and received as a lyophilized powder.
Trypsin and chymotrypsin were purchased from Promega (Madison, WI) and mass spectrometrygrade water, acetonitrile and formic acid from Fisher Scientific (Fair Lawn, NJ).
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2.3.1

Sample Preparation

ApoMb was dissolved in potassium phosphate buffer (20 mM, pH 7.4) to produce a stock solution
of 200 µM protein and the solution was dialyzed using Biotech Cellulose Ester dialysis tubing
(MWCO 8,000-10,000 Da, Spectrum Laboratories, Rancho Dominguez, CA) for 24 h into the same
buffer. After dialysis, the solution was filtered through a 0.2 µm syringe filter (Gelman Nylon
Acrodisc 13) and used for further experiments. Sucrose stock solution (33.9 mg/mL) was prepared
by dissolving sucrose in potassium phosphate buffer and filtering through a 0.2 µm syringe filter.
The resulting solution was stored at 4 °C until use. A stock solution of pLeu (30 mM) was prepared
similarly. Lyophilization was carried out with different ratios of protein to pLeu using a VirTis Plus
AdVantage freeze dryer (SP Industries Inc., Gardiner, NY). ApoMb, sucrose and pLeu stock
solutions were mixed such that the final protein concentration was 100 µM, the protein to sucrose
ratio was 1:2 w/w and the protein to pLeu molar ratio was 1:20, 1:50 or 1:100. Control samples
contained apoMb and sucrose without pLeu. The final volume for lyophilization was 80 µL. In order
to produce a pharmaceutically relevant formulation, ~ 50 % or more of the solid matrix consisted of
sucrose, and buffer was less than 10 % of the formulation by weight (Table 2.1).

All samples were lyophilized in vials made of borosilicate clear glass using an established
conservative freeze-drying cycle. During the lyophilization cycle, the shelves were precooled to 2 °C. Freezing was carried out at -40 °C for 50 min, followed by drying under vacuum (70 mTorr)
over 5 steps (-35 °C for 10 h, -20 °C for 8 h, -5 °C for 6 h, 10 °C for 6 h and 25 °C for 6 h). The
lyophilized samples were stored at -20 °C until use. Solution controls were prepared at each
composition.
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Table 2.1. Composition of lyophilized formulations containing apomyoglobin (apoMb)a and photoleucine (pLeu)b

Composition (%w/w)

apoMb:pLeu
molar ratio

ApoMb

Sucrose

pLeu

Buffer

No pLeu

31.0

61.9

0.0

7.1

1:20

29.4

58.5

5.0

6.8

1:50

27.4

54.8

11.6

6.3

1:100

24.5

49.1

20.7

5.6

2.3.2

Photolytic Labeling and MS Analysis of Intact Protein

Photolytic labeling was carried out using a UV Stratalinker 2400 equipped with five 365 nm UV
lamps (Stratagene Corp., La Jolla, CA). The lamps were allowed to warm up for 5 min. Vials
containing lyophilized samples and solution controls were uncapped and placed inside the UV
chamber. The distance between the lamps and the cake at the bottom of the vial was approximately
15 cm. All samples were irradiated with UV light for 40 min. After irradiation, the solid was
reconstituted with 800 µL of Solution A (A= 0.1 % formic acid in MS water) to give a final protein
concentration of 10 nmol/mL. The solution formulation was diluted similarly. The samples were
diluted further with Solution A and 20 pmol of protein was injected into the HPLC-MS system. Intact
labeled protein was analyzed using HPLC-MS equipped with an ESI source (1200 series LC, 6520
qTOF; Agilent Technologies, Santa Clara, CA). Mass spectra were processed and deconvoluted
using MassHunter software (Agilent Technologies).
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Percentages of protein populations with 1 through 6 labels were calculated using peak heights from
extracted ion chromatograms:

% Li = PHi/ (PHi + PHu) x 100

Equation 2.1

where i denotes the number of labels (1-6), PHi denotes the peak height for labeled protein Li and
PHu denotes the peak height of the unlabeled protein as observed by mass spectrometry.
Hereinafter, the term ‘unlabeled’ will refer to a protein/peptide that has been exposed to pLeu and
irradiation, but was not labeled, while the term ‘native’ will refer to a protein/peptide that has not
been exposed to pLeu and irradiation.

2.3.3

Effect of Irradiation Time and pLeu concentration on Labeling Efficiency

ApoMb lyophilized with sucrose and pLeu (1:100 molar ratio protein: pLeu, which is equivalent to
20.7 % w/w pLeu) was used to study the kinetics of photolytic labeling. Lyophilized samples were
subjected to photolysis for different periods of time (0, 0.5, 2, 4, 10, 20, 30, 40 and 60 min). The
samples were reconstituted and analyzed as described above. In a separate study, apoMb was
lyophilized with sucrose and varying pLeu concentrations (0, 0.3, 1.3, 1.5, 2.5, 11.6 and 20.7 %
w/w). The solid was irradiated at 365 nm for 40 min, reconstituted and analyzed for labeled protein.
The fraction of labeled protein (FL) was calculated using peak heights from extracted ion
chromatograms:

FL = 1 – [PHu/(PHu + PHL)]

Equation 2.2

where PHL denotes the peak height for labeled protein and PHu denotes the peak height of the
unlabeled protein as observed by mass spectrometry. FL represents the sum of populations of
apoMb with 1-6 labels.
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2.3.4

MS- and MS/MS- Analysis of Labeled apoMb Peptides

To identify the sites of photolytic labeling, apoMb was lyophilized with sucrose and pLeu as
described above using 0, 0.3, 1.3, 1.5, 2.5, 11.6 and 20.7 % w/w pLeu. The solid was irradiated at
365 nm for 40 min and then reconstituted in ammonium bicarbonate buffer (100 µM, pH 8.0) to give
a protein concentration of 10 nmol/mL. Enzymatic digestion of labeled apoMb was performed for
24 h at 60 oC using a combination of trypsin and chymotrypsin (1:1 molar ratio) at a total enzyme
to protein molar ratio of 1:10. The reaction was then quenched with solution A and 20 pmol was
injected into the LC-MS system. The proteolytic fragments were separated on a ZORBAX 300SBC18 column (Agilent Technologies; 1.0 x 50 mm, particle size 3.5 µm). The column was equilibrated
with 5% Mobile Phase B (B= 0.1 % formic acid in acetonitrile) and peptides were eluted at 50
µL/min using a gradient that increased from 5 to 45% B over 22 min and then from 45 to 95% B
over 0.5 min. Mass spectra were processed using MassHunter and a theoretical digest map (with
known sites of enzymatic cleavage, and allowing for up to 8 missed cleavages) was used to create
a mass list for peptides carrying 0 through 7 labels. This theoretical list was matched against mass
values obtained experimentally.

Based on this analysis, up to 15 labeled peptides were detected that carried one, two or four labels.
One of these peptides, L32-K42 (LFTGHPETLEK) with one label was selected for MS/MS analysis.
This precursor peptide had m/z = 462.9133 (z = +3) and was subjected to fragmentation using lowenergy CID (Agilent Technologies), which predominantly produces b- and y-ions. Product ions were
identified using MassHunter software.

2.3.5

Formulation Effects

In order to study the effect of excipients on side-chain environment, apoMb was lyophilized with
100x molar excess of pLeu in two formulations: the first with sucrose (1:2 w/w ratio of protein to
sucrose) and the second with guanidine hydrochloride (Gdn HCl; 1.5 M final concentration). The
final protein concentration was 100 μM and the concentration of pLeu was 20.7 % w/w (sucrose
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formulation) or ~ 1 % w/w (Gdn HCl formulation). The lyophilized formulations were subjected to
photolysis at 365 nm for 40 min. After reconstitution with ammonium bicarbonate buffer, the
samples were digested with trypsin and chymotrypsin and peptide-level MS analysis was carried
out as described above.

2.3.6

Photolytic Labeling with p-Benzoyl-L-Phenylalanine (pBpA)

GCG (1-8)* was dissolved in water to give a final concentration of 1 mM. The peptide was
lyophilized alone or with one of the following excipients: sucrose, trehalose, urea, L-methionine and
L-leucine (1:2 w/w ratio of peptide to excipient). After lyophilization, the formulations were irradiated
with UV light (365 nm) for 30 min. The irradiated samples were then reconstituted in 200 μL of MS
water containing 0.1 % formic acid. Solution controls prepared with or without excipients were
lyophilized and reconstituted before irradiation. The samples were further diluted to 20 pmol of
peptide for injection into the LC-MS system. MassHunter software was used to detect peptidepeptide and peptide-excipient adducts.

Photolytic labeling with GCG (1-8)* was also carried out with pLeu in the matrix. Two formulations
were prepared. The first contained GCG (1-8)* and pLeu at a 1:1 molar ratio, while the second
contained GCG (1-8)* and pLeu at a 1:1 molar ratio, together with sucrose (1:2 w/w ratio of GCG
(1-8)* to sucrose). Both formulations were lyophilized as described above, irradiated with UV light
for 30 min, reconstituted and analyzed by ESI-LC-MS. Solution controls were prepared and
analyzed as described above.

2.3.7

MS/MS Analysis of GCG (1-8)* Dimer

Both lyophilized and solution formulations showed the presence of GCG (1-8)* dimer. LC-MS/MS
was carried out on GCG (1-8)* monomer (m/z 968.41, z= +1) and GCG (1-8)* dimer (m/z 646.28,
z= +3) in the peptide-Leu formulation. CID fragmentation was performed at 10 V and the resultant
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b- and y-ions were monitored. The dimer from solution controls (unlyophilized solution and
lyophilized-rehydrated solution) was also analyzed by MS/MS.

2.4
2.4.1

RESULTS

Intact Protein Labeling

The mechanisms of photolytic labeling with pLeu in solution are well understood18,
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Briefly,

photolysis of pLeu at 365 nm results in the loss of N2 with the generation of a reactive carbene. The
carbene labels any C-C, C=C or X-H group (X=C, O, N, S) in its proximity without bias towards a
particular amino acid or functional group. Photolabeling of myoglobin with pLeu has been carried
out in solution, with successful labeling at a 1:10,000 molar ratio of protein to pLeu18. Here, we
investigated the covalent labeling of apoMb with pLeu in lyophilized solids. Intact protein was colyophilized with sucrose and pLeu as excipients in weight fractions that are pharmaceutically
relevant.

Mass spectrometric analysis of lyophilized solids containing apoMb and pLeu showed that carbene
labeling also occurs in the solid state. Peaks corresponding to labeled protein were observed, with
masses differing by multiples of ~115 amu (Fig. 2.1). The extent of labeling depended on the
amount of pLeu in the matrix. Peaks corresponding to singly- and doubly-labeled apoMb
populations were observed when apoMb was lyophilized with a 20-fold molar excess of pLeu (Fig.
2.1). Similarly, peaks corresponding to up to 4 and 6 labels per protein molecule were observed for
the 1:50 and 1:100 formulations, respectively. ApoMb lyophilized without pLeu showed no adduct
formation after irradiation (data not shown), confirming that UV light did not cause protein crosslinking. Also, protein lyophilized with pLeu showed no labeling in the absence of UV light (data not
shown). Moreover, solution controls showed no labeling of apoMb with 20-, 50-, 100- or 1000-fold
molar excess of pLeu (data not shown), suggesting that the reactive carbene species was
consumed by reaction with water rather than reacting with protein.
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Figure 2.1 Deconvoluted mass spectra of native ApoMb (N) and ApoMb co-lyophilized with sucrose
(1:2 w/w ratio of protein to sucrose) and pLeu in molar ratios 1:20, 1:50 and 1:100. Mass spectra
show peaks for unlabeled apoMb (U) and labeled apoMb (nL) (n=1-6). The peaks differ by ~ 115
amu, corresponding to the mass of one pLeu label.

2.4.2

Labeling Kinetics

During exposure of solid samples to UV irradiation, the fraction of labeled protein increased with
time (Fig. 2.2A). The rate of formation of labeled protein was rapid initially and plateaued at ~30
min with ~20% of the protein remaining unlabeled (Fig. 2.2A). Labeling followed monoexponential
kinetics as a function of irradiation time. To determine the effect of pLeu concentration on the
plateau value, the extent of labeling was measured at different initial concentrations of pLeu with
40 min of irradiation (Fig. 2.2B). At 0 % w/w pLeu, no labeling occurred. As pLeu concentration was
increased, the fraction of labeled protein increased until at 20.7 % w/w pLeu, ~35 % unlabeled
protein remained after 40 min of irradiation. The dependence of the extent of modification on pLeu
concentration also followed monoexponential behavior.

An exponential model was used to simultaneously fit the rate and extent of labeling:
FL(C, t) = A(1-e-k1t)(1-e-k2C)

Equation 2.3
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where FL(C, t) is the fraction of labeled protein as a function of pLeu concentration (C) and
irradiation time (t), k1 and k2 are apparent first-order rate constants for the rate and extent of labeling,
respectively, and A is the fraction of protein labeled at plateau. Nonlinear regression (Origin Pro
v.8.6, OriginLab, Northampton, MA; n = 48) returned values of the regression parameters of A =
0.82 (±0.03), k1= 0.22 min-1 (±0.02) and k2= 0.12 mM-1 (±0.01).

Figure 2.2. (A) Kinetics of photolytic labeling of apoMb in lyophilized solids containing 20.7 % w/w
pLeu in the matrix, 365 nm irradiation. The solid line is fit to Eqn. 2.3. n = 3 ± SD. (B) Dependence
of ApoMb photolytic labeling on the concentration of pLeu after 40 min irradiation at 365 nm. The
solid line is fit to Eqn. 2.3. n = 3 ± SD.

2.4.3

Peptide Labeling

In order to investigate the specificity of labeling, sites of labeling were probed using bottom-up
mass spectrometry. Digestion of native apoMb with trypsin/chymotrypsin produced 36 peptides, of
which 13 were selected to provide 100 % sequence coverage (Appendix, Fig. A1). Labeled apoMb
showed ~ 96 % sequence coverage and a maximum of fifteen peptide fragments (obtained with
20.7 % w/w pLeu) with one, two or four labels (Fig. 2.3). As expected, the signal intensity of labeled
peptides was less than that of unlabeled peptides, supporting the incomplete labeling observed at
the intact protein level. Proteolytic digestion was influenced by the presence of pLeu labels: both

29

the labeled and unlabeled peptides obtained after digestion of labeled apoMb differed from those
in the native protein. This suggests that the label interferes with digestion by obstructing access by
the enzyme.
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Figure 2.3. Digest map of apoMb labeled with 10 mM pLeu. Labeled apoMb was digested with a
combination of trypsin and chymotrypsin. White bars represent unlabeled peptides, while labeled
peptides are shown in gray (light gray bars carry one label; dark gray bars carry two labels and the
black bar carries four labels). Dashed lines represent native peptides. Helical secondary structure
is represented by cylinders labeled A-E, G and H. Helix F of holomyoglobin (H82-H97) is disordered
in native apoMb at neutral pH27.
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As the concentration of pLeu increased, labeling was detected in different regions of the protein
(Fig. 2.4). Labeling at the peptide level was obtained using MS analysis of digested labeled apoMb
at various pLeu concentrations (Fig. 2.4(b-h)). At 0 % w/w pLeu, no labeling was observed (Fig.
2.4b). At 0.3 % w/w pLeu, peptides L32-K42 and T34-K42 were labeled (Fig. 2.4c). This region
forms helix C and part of helix B. At 1.3 % w/w pLeu, an additional peptide HKIPIKY (H97-Y103;
located on a loop and part of helix G) was labeled (Fig. 2.4d). As pLeu concentration was increased
to 2.5 % w/w, labeling was detected in peptide H119-F138 (helix H) in addition to L32-K42, T34K42 and H97-Y103 (Fig. 2.4e). At 5 % w/w and 11.6 % w/w pLeu, Y103-K133 was labeled as well
(Fig. 2.4f, g). At 20.7 % w/w pLeu, label was detected in G1-W14, G1-R31, V17-K42 (helices A, B
and C), H48-K56 (helix D), H97-K102 (helix G), G124-F138, N140-F151, Y146-G153, E148-F151
and R139-G153 (helix H), in addition to the previously mentioned sequences (Fig. 2.4h). Increased
label uptake at the C terminus is consistent with our previous solid-state hydrogen-deuterium
exchange (ssHDX-MS) results for myoglobin, which showed greater deuterium uptake in this region
even in the solid state16. Overall, labeling was observed across helices A, B, C, D, G and H. No
labeling was observed on amino acids A57-K96, which form helices E and F. These two helices
are involved in heme binding in holomyoglobin (holoMb), but are considerably disordered in
apoMb27, 28. The absence of label suggests that this region is protected from matrix exposure at the
tertiary structure level in the solid state.
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Figure 2.4. (a) Ribbon diagram of apoMb showing helices A-E, G and H. (b-h) Ribbon diagram of
apoMb showing covalent labeling with increasing amounts of pLeu in the matrix in the presence of
sucrose. (b) 0 (c) 0.3 (d) 1.3 (e) 2.5 (f) 5.0 (g) 11.6 (h) 20.7 %w/w pLeu. (i) Ribbon diagram of
apoMb showing covalent labeling with 20.7 % w/w pLeu in the presence of Gdn HCl (1.5 M). The
ribbon diagrams were generated using PyMOL (PyMOL Molecular Graphics System, Version 1.4.1,
Schrödinger, LLC) and the crystal structure of myoglobin (PDB ID 1WLA; www.rcsb.org). Helix F
(H82-H97) in the myoglobin structure was modified to an unstructured region, which is observed
for native apoMb at neutral pH27.
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2.4.4

MS/MS Analysis of Peptide L32-K42 (LFTGHPETLEK)

To obtain additional information on the sites of photolytic labeling, tandem MS analysis was carried
out on the singly-labeled peptide L32-K42, both in the labeled and native form. After fragmenting
the native peptide, almost all b- and y-ions were observed (Appendix, Table A1, I and II). However,
no b-ions were observed in the labeled peptide product ion mass spectrum. Six y-ions (y6, y7, y8,
y9, y10 and y11) with z = +2 and three y-ions (y4, y5 and y6) with z = +1 were identified by fragmenting
the labeled peptide at 13 V (Fig. 2.5; Appendix Table A1, III and IV). Unlabeled y-ions (y1-y10) were
also observed upon fragmentation of the labeled peptide (Appendix, Table A1, III and IV; dotted
arrows in Fig. 2.5). Assuming that the ionization and fragmentation efficiencies of the labeled and
native peptides are similar, and that the instrument is sensitive toward all possible labeled and
unlabeled ions, the results suggest two possible reasons for the differences in fragmentation
patterns: (1) Labeling is site-specific at Thr (peptide TLEK), since unlabeled y1-y3 and labeled y4y11 were observed. The presence of unlabeled y4-y10 could indicate loss of label from Thr during
fragmentation. (2) Labeling is heterogeneous, with multiple sites of modification ranging from Leu
to Thr (peptide LFTGHPET), since labeled y4-y11 and unlabeled y1-y10 were observed. The presence
of unlabeled y1-y10 may be due to neutral loss of label from any of the labeled amino acids in peptide
LFTGHPET. The absence of b-ions in the product ion spectrum of the labeled peptide makes it
difficult to establish the cause of the differences in labeling pattern.
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Figure 2.5. MS/MS spectrum of labeled peptide L32-K42 showing y-ion products obtained by CID
fragmentation. The asterisk indicates the precursor peptide peak (m/z = 462.91). Dashed arrows
represent y-ion peaks produced from the labeled peptide and dotted arrows represent y-ion peaks
produced by possible loss of the label from the corresponding labeled y-ions. Labeled y-ions y11
(z=+2) and y5 (z=+1) are not shown due to low abundance.

2.4.5

Formulation Effects

ApoMb lyophilized with Gdn HCl and 100x molar excess of pLeu (~ 1% w/w pLeu) was analyzed
for label uptake at the peptide level. MS analysis after enzymatic digestion showed that labeling
occurred at peptides L32-K42, T34-K42 and H119-F138 (Fig. 2.4(i)). This is similar to the labeling
observed with sucrose at 2.5 % w/w pLeu, but with no labeling on the G helix (at the BG contact
interface). Gdn HCl is expected to have a chaotropic effect on protein structure and to cause
increased label uptake due to protein unfolding and higher solvent exposure. In contrast, sucrose
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is expected to preserve the native structure of the protein through preferential exclusion and show
lower labeling. These differences between expected and observed labeling patterns may be
attributed to changes in protein side-chain environment caused by Gdn HCl.

2.4.6

Photolytic Labeling with p-benzoyl-L-phenylalanine (pBpA)

GCG (1-8)* lyophilized with and without excipients and irradiated in the solid state showed the
formation of peptide-peptide adducts. Peptide dimers and trimers were observed by ESI-LC-MS;
these adducts were also present in solution controls. Peptide-excipient adducts were also observed,
but not for all formulations. Only two formulations (peptide-Met and peptide-Leu) showed peptideexcipient adducts in both solid and solution, while the sucrose, trehalose and urea formulations
showed no peptide-excipient adducts in either solid or solution state (Table 2.2).

The first formulation containing GCG (1-8)* and pLeu showed several adducts in the lyophilized
formulation. Cross-linking occurred between GCG (1-8)* and itself (dimer and trimer) and between
GCG (1-8)* and pLeu (with and without the loss of N2). The solution control showed GCG (1-8)*
adducts (dimer and trimer) and GCG (1-8)*-pLeu adducts with the loss of N2. The second
formulation containing GCG (1-8)*, pLeu and sucrose produced peptide adducts (dimer and trimer),
peptide-pLeu adducts (with and without the loss of N2), pLeu-sucrose adducts with the loss of N2
and peptide-pLeu-sucrose adducts with the loss of N2. The solution control showed GCG (1-8)*
adducts (dimer and trimer) and peptide-pLeu adducts (with the loss of N2), but no adducts with
sucrose.
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Table 2.2. Cross-linked products formed after irradiation of GCG (1-8)* in various lyophilized
formulations
Cross-linked Products
Formulation

State

GCG (1-8)*

GCG (1-8)*

GCG (1-8)*

GCG (1-8)* +

Monomer

Dimer

Trimer

Excipient
Adduct

GCG (1-8)* alone

Solid

+

+

+

N/A

Solution

+

+

+

Solid

+

+

+

-

Solution

+

+

+

-

Solid

+

+

+

-

Solution

+

+

+

-

Solid

+

+

+

+

+

+

+

+

Solid

+

+

+

+

Solution

+

+

+

+

Solid

+

+

+

-

+

+

-

+

+

+d,e

N/A
GCG (1-8)* +
Sucrosea
GCG (1-8)* +
Trehalosea
GCG (1-8)* + Lmethioninea
GCG (1-8)* + L-

Solution

leucinea
GCG (1-8)* +
Ureaa

+
Solution

Formulation Ab

Solid

+

+d
Formulation Bc

Solution

+

+

+

Solid

+

+

+

Solution

+

+

+

+ d,e,f,g
+d
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a

Excipients were added in a 2:1 w/w ratio with GCG (1-8)*.

b Formulation
c

A = GCG (1-8)* and pLeu in a 1:1 molar ratio.

Formulation B = GCG (1-8)*, pLeu and sucrose, with a 1:1 molar ratio of GCG (1-8)* and
pLeu and 1:2 w/w ratio of GCG (1-8)* and sucrose.

d GCG

(1-8)* + pLeu adduct with loss of N2.

e GCG

(1-8)* + pLeu adduct without loss of N2.

f pLeu
g GCG

+ sucrose adduct with loss of N2.
(1-8)* + pLeu + sucrose adduct with loss of N2.

2.4.7

MS/MS Analysis of GCG (1-8)* Monomer and Dimer

All b-ions (b1-b8; z=+2) and several y-ions were detected after CID fragmentation of GCG (1-8)*
monomer (data not shown). Fragmentation of the dimer from lyophilized formulations produced
cross-linked product ions in addition to internal fragment (non-cross-linked) b- and y-ions (Fig. 2.6;
Appendix Table A2, I and II). In order to assign product ions to cross-linked sequences, the
nomenclature proposed by Schilling and coworkers was used29. GCG (1-8)* monomer was
designated as α, while b- and y-ions (from the second monomer unit in the dimer) cross-linked with
α were designated as b~α- and α~y-ions. The following cross-linked ions were detected: b4~α, b5~α,
b6~α, b7~α, α~y5 and α~y6. Internal fragment product ions b1, b2, b3, b5, y1, y2, y3 and y4 were also
detected. The evidence suggests that, for lyophilized GCG (1-8)*, peptide-peptide cross-linking
occurs preferentially between pBpA and Gly residues.

In solution controls, the fragmentation of the GCG (1-8)* dimer also produced internal fragment
ions and cross-linked product ions (data not shown). An unambiguous assignment of the site of
cross-linking could not be made, however, suggesting multiple sites of cross-linking in solution.
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Figure 2.6. MS/MS spectrum of GCG (1-8)* dimer in the lyophilized formulation with L-leucine
showing b- and y-ion products obtained by CID fragmentation. The asterisk denotes the precursor
dimer peak (m/z = 646.28). Closed circles represent simple (non-cross-linked) b- and y-ions. Open
circles represent cross-linked b- and y-ions, labeled as b~α and α~y. Inset shows b- and y-ion
sequences for internal fragment ions (numbered in grey) and cross-linked ions (numbered in black)
detected.

2.5

DISCUSSION

The studies presented here demonstrate successful photolytic labeling with pLeu and pBpA in
lyophilized powders. To our knowledge, this is the first reported use of PAAs to study protein-protein
and protein-matrix interactions in amorphous solids, though previous studies have employed PLMS in solutions in liquid and frozen states. For example, PL-MS using pLeu has been reported in
solution for myoglobin and calmodulin18 using a 1:10,000 molar ratio of protein to pLeu and a pulsed
laser for irradiation. Calmodulin was detected carrying up to 4 labels, while myoglobin showed up
to 2 labels. Our studies with apoMb were unable to detect covalent labeling in solution at a 1000x
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molar excess of pLeu. This may be due to differences in irradiation energy in the two studies.
However, solid state labeling with 100x molar excess of pLeu showed up to 6 labeled populations
in our studies, suggesting that labeling with pLeu is more efficient in the solid state than in solution,
perhaps due to greater proximity of protein and pLeu, low water content and/or reduced mobility in
the solid state.

PL-MS with pLeu has also been used previously to study the effect of carbene diffusion and solvent
accessibility in frozen calmodulin solutions30. In frozen solutions, Jumper et al observed labeling at
multiple sites, with higher labeling yields at Glu and Asp and no correlation with solvent accessibility.
They proposed that pre-concentration of pLeu at the protein surface prior to freezing (driven by
electrostatic interaction) and carbene diffusion (driven by temperature) dictated preferential labeling
at carboxylate groups. In our studies in lyophilized solids, site-specific labeling such as this was not
detected, though we were able to localize the label to the peptide level. Jumper et al used highenergy collisional dissociation (HCD) and electron-transfer dissociation (ETD), rather than the CID
fragmentation used here. It is possible that CID fragmentation may have caused some loss of label,
as has been reported previously30, 31. Alternatively, there could be multiple sites of labeling in the
lyophilized samples, as expected given the non-specific nature of carbene reactivity. Kolbel and
coworkers observed multiple cross-links between pLeu and Gly, Leu and Tyr when pLeu was
incorporated within a peptide sequence and irradiated in solution19. Their results indicated
preferential labeling based on secondary structural constraints, rather than chemical reactivity.

Though our results do not support preferential labeling of specific functional groups, preferential
labeling was observed at the peptide level in lyophilized samples, which varied with the pLeu
content of the solid (Fig. 2.4 (b-h)). Interestingly, the peptides labeled preferentially (i.e., labeled at
the lowest pLeu concentrations and at higher concentrations) correspond to those in the molten
globule of apoMb in solution. In solution, apoMb has molten globule characteristics at neutral pH,
with helices A, G and H forming its core32. The most commonly accepted folding pathway is AGH

39
→ ABGH → ABCDEGH33. Interactions between the BG helix pair are critical in maintaining the
stability of the AGH core and promoting favorable interactions between the GH helix pair34, 35. BG
and GH interactions cause the largest decrease in solvent accessible surface area upon folding36.
These interactions are also thought to destabilize helices E and F, which are less stable than
helices A, B, G and H35, 37. Our ssPL-MS data showed that helices B, G and H are among the first
to be labeled at lower pLeu concentrations, while helices E and F show no label uptake even at
pLeu higher concentrations. This suggests that the molten globule is intact in lyophilized solids
and is preferentially labeled, perhaps because amino acid side chains are exposed to pLeu in the
matrix when the helices are intact. Interaction of pLeu with these regions prior to lyophilization
cannot be ruled out, however.

ssPL-MS was also used to examine formulation effects on the side-chain environment, with peptide
level resolution. In the presence of sucrose and 100x molar excess of pLeu (20.7 % w/w pLeu),
apoMb showed labeling on all helices except E and F. When Gdn HCl was included as an excipient,
CD spectroscopy of the solution prior to lyophilization showed loss of signal at 222 nm and 208 nm
(data not shown), confirming that the protein had lost helicity. We expected that the Gdn HCl
unfolded protein would remain unfolded after lyophilization and would be labeled to a greater extent
than folded protein (e.g., in sucrose, as in our previous ssHDX studies17, 38). Instead, photolytic
labeling was less in solids containing Gdn HCl than in those containing sucrose. This may be due
in part to the high mass fraction of Gdn HCl in the lyophilized solid (~0.97), limiting interaction
between the protein and pLeu by simple dilution. The high Gdn HCl fraction in the solid is the result
of the high molar concentration used to unfold apoMb in solution, and is greater than the mass
fraction of sucrose (~0.50) in the sucrose formulation. Preferential interaction of guanidinium ions
with apoMb may also contribute, blocking protein-pLeu interactions and thereby inhibiting pLeu
labeling39. Similarly, the high ionic strength of the Gdn HCl solutions prior to lyophilization may
inhibit ionic interactions between pLeu and apoMb, so that labeling is reduced.
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To complement studies with pLeu incorporated into the matrix as an excipient, studies were also
performed with a PAA incorporated into the peptide sequence. This approach has been used to
map the interactome in cells and to study PPIs in vitro21, 40, 41. The studies used an octapeptide
derived from the N-terminal sequence of glucagon (GCG (1-8)*), with pBpA at the F6 position.
Glucagon is a 29 amino-acid peptide used to treat insulin-induced hypoglycemia. The monomeric
peptide is relatively unstructured in solution, but forms fibrils in acidic and alkaline pH42-44. Previous
experimental and computational reports have assigned higher aggregation tendency to glucagon’s
N- and C-termini44-46. For example, Pedersen et al used experimental Ala mutation to study
glucagon aggregation in solution and observed that mutations at residues F6, Y10, V23 and M27
decreased the rate of fibrillation at acidic pH44. Their results indicated that regions 6-10 and 23-27
are involved in fibrillation. Solution-state HDX-NMR studies have also indicated involvement of the
N-terminus in aggregation45.

We used GCG (1-8)* to study peptide-peptide and peptide-matrix interactions of the N-terminal
sequence in solution and in the solid state, in the presence of various excipients. In solid samples,
adducts of pBpA with L-Met and L-Leu excipients were observed. Adducts were not detected in
lyophilized solids containing sucrose, trehalose or urea. The formation of adducts with L-Met and
L-Leu may be attributable to their free, electron-rich C-H groups, which are known to react with the
ketyl radical of pBpA26, 47. Preferential exclusion of sucrose and trehalose from the vicinity of the
peptide in the pre-lyophilized solution48, 49 may contribute to the lack of adduct formation with these
excipients. Urea was selected as a negative control, since it has no C-H groups and hence is not
expected to form adducts with pBpA, as was observed. In addition to protein-matrix interactions,
studies with GCG (1-8)* were able to capture PPIs at the interface of dimers in the solid state, with
amino acid-level resolution. The studies showed that the pBpA label interacts preferentially with G6
in forming the dimer (Fig. 2.6). In contrast, there appear to be multiple cross-linking sites in solution,
perhaps due to greater mobility of the peptide in solution and/or multiple alignments of two
monomer units.
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Formulations containing both GCG (1-8)* and pLeu, with and without sucrose, were used to
examine interactions in the solid state and in solution. In these studies, photolytic labels are present
in both the peptide sequence and in the matrix. Following photoirradiation, peptide dimers and
trimers, binary adducts of GCG (1-8)* with pLeu, binary adducts of pLeu with sucrose, and ternary
adducts containing GCG (1-8)*, pLeu and sucrose were detected (Table 2.2). The two PAAs (i.e.,
pLeu, pBpA) are activated at the same wavelength, but have different mechanisms of labeling. The
formation of a peptide-pLeu complex with the loss of N2 is consistent with the mechanism of
carbene labeling through pLeu activation, while adducts formed without the loss of N2 are consistent
with labeling through pBpA activation. In solids containing binary mixtures of GCG (1-8)* and pLeu,
both types of adducts were detected, indicating activation and labeling via both pLeu and pBpA
(Formulation A, Table 2.2). In solution, products were detected only with loss of N2 indicating adduct
formation via pLeu and not via pBpA, perhaps due to reaction of activated pBpA with water. In
solids containing GCG (1-8)*, pLeu and sucrose (Formulation B, Table 2.2), ternary adducts were
detected with the loss of N2, indicating participation of both PAAs in the formation of the adduct. It
is unlikely that GCG (1-8)* interacts with sucrose directly in these ternary adducts, since it did not
form adducts with sucrose in the binary formulation. Together, these studies with samples
containing both GCG (1-8)* and pLeu show that peptide-peptide and peptide-matrix interactions
can be detected, and that reactivity of the two PAAs differs in solution and in the solid state.

The irreversible nature of photolytic labeling and complementarity to ssHDX-MS makes ssPL-MS
a useful tool to study the protein environment in lyophilized powders. The primary advantage of
using a PAA in the excipient matrix is the ease of labeling; the PAA simply needs to be added in
an appropriate concentration to the pre-lyophilized solution. Moreover, since the PAA is only
activated at a certain wavelength range and has a very short lifetime (nanosecond scale for singlet
state carbene in solution, 80-120 μs for ketyl radicals in the triplet state in solution26,

50),

the

photolabeling reaction can be better controlled than with other labeling reagents such as sulfo-Nhydroxysuccinimide acetate (NHSA) that require quenching and removal of excess unreacted
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reagent. Another benefit of the non-specific diazirine chemistry is that the entire protein structure
can be probed, as opposed to reagents such as NHSA and 2,3- butanedione that target only lysine,
N-terminal amino acids and arginine. However, non-specific labeling with diazirine-based probes
poses analytical challenges. Our results showed that ssPL-MS with apoMb and pLeu could identify
the location of the label at the peptide level, but MS/MS using CID failed to provide amino acidlevel resolution. Labeling with PAAs incorporated in the protein sequence overcomes this hurdle
by localizing the site of labeling to particular amino acid(s), with the attendant disadvantage that
the PAA-labeled peptide/protein must first be synthesized. Incorporating the label in the protein
sequence provided residue-level information about the sites of interaction, as shown with GCG (18)*.

The results have implications for formulation design and stability testing in the biopharmaceutical
industry. The high resolution of ssPL-MS can facilitate rational design of formulations by allowing
excipients to be selected and created based on their interactions with the protein side-chain. The
information can also be used to improve protein drugs themselves through protein engineering.
Ongoing work in our laboratory is developing alternate approaches to incorporate photolytic label
into the protein sequence, including the use of auxotrophic cell lines and site-directed mutagenesis
51, 52.

The use of heterobifunctional cross-linkers such as succinimidyl 4,4’- azipentanoate, which

contains a primary amine-specific NHS functional group and a non-specific diazirine functional
group, is also being explored as an alternative approach to label incorporation.

2.6

CONCLUSIONS

Peptide-level information about protein structure and environment in lyophilized formulations was
obtained using ssPL-MS. Photoactive probes can be used externally in the matrix or incorporated
within the protein/peptide sequence to study side-chain accessibility or visualize protein-matrix
interactions respectively.
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CHAPTER 3.

PHOTOLYTIC CROSSLINKING TO PROBE MOLECULAR INTERACTIONS IN
LYOPHILIZED SOLIDS

This chapter was published as a research article in Molecular Pharmaceutics (2013) and can be
found online at http://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.5b00183

3.1

ABSTRACT

Protein structure and local environment in lyophilized formulations were probed using highresolution solid-state photolytic crosslinking with mass spectrometric analysis (ssPC-MS). In order
to characterize structure and microenvironment, protein-protein, protein-excipient and proteinwater interactions in lyophilized powders were identified. Myoglobin (Mb) was derivatized in solution
with the heterobifunctional probe succinimidyl 4,4’-azipentanoate (SDA), and the structural integrity
of the labeled protein (Mb-SDA) confirmed using CD spectroscopy and liquid chromatography /
mass spectrometry (LC-MS). Mb-SDA was then formulated with and without excipients (raffinose,
guanidine hydrochloride (Gdn HCl)) and lyophilized. The freeze-dried powder was irradiated with
ultraviolet light at 365 nm for 30 min to produce crosslinked adducts that were analyzed at the intact
protein level and after trypsin digestion. SDA-labeling produced Mb carrying up to 5 labels, as
detected by LC-MS. Following lyophilization and irradiation, crosslinked peptide-peptide, peptidewater and peptide-raffinose adducts were detected. The exposure of Mb side chains to the matrix
was quantified based on the number of different peptide-peptide, peptide-water and peptideexcipient adducts detected. In the absence of excipients, peptide-peptide adducts involving the CD,
DE and EF loops and helix H were common. In the raffinose formulation, peptide-peptide adducts
were more distributed throughout the molecule. The Gdn HCl formulation showed more proteinprotein and protein-water adducts than the other formulations, consistent with protein unfolding and
increased matrix interactions. The results demonstrate that ssPC-MS can be used to distinguish
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excipient effects and characterize the local protein environment in lyophilized formulations with high
resolution

3.2

INTRODUCTION

Protein drugs are the fastest growing sector of the pharmaceutical industry, a trend likely to
continue given multiple impending patent expirations and a crowded biosimilars pipeline 1. A
distinguishing feature of protein drugs is the relationship between conformation, dynamics and
biological function. The three-dimensional structure of proteins is the result of hydrophobic,
covalent and electrostatic interactions and hydrogen bonding, and can be disrupted during
manufacture, formulation and storage. It is generally accepted that maintaining a near-nativeconformation in the formulation is essential for both efficacy and safety. Misfolded or partially
unfolded species are often more prone to degradation and/or aggregation, complicating
manufacturing and increasing the potential for adverse immunogenic reactions in patients. With the
emergence of biosimilars, extensive characterization of protein structure is required to demonstrate
that the product is “highly similar” to the reference product; hence, it is even more essential to
reliably characterize protein structure in both solid and solution formulations with sufficient
resolution.

Though proteins are often lyophilized to preserve structure during API storage and/or in the final
formulation, degradation and aggregation can occur during the freeze-drying process, storage and
reconstitution

2-4.

Stabilizers such as disaccharides offer some protection, but are not always

effective. As a result, formulation is often a largely trial-and-error process, and can be timeconsuming and expensive. Moreover, the structure of proteins in lyophilized solids is not well
studied by conventional techniques, further hindering the formulation process.

Lyophilization typically produces an amorphous solid powder, unless crystallizing excipients such
as mannitol are used. Formulations containing cryoprotective disaccharides such as sucrose and
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trehalose have demonstrated the ability to retain native protein structure and activity

5-7.

Two

hypotheses have been proposed to explain this stabilization: (1) the water replacement theory,
which asserts that carbohydrates substitute for water and form hydrogen bonds with the protein
and (2) the vitrification theory, which claims that the formation of a glassy solid reduces protein
mobility and so preserves structure and stability. While support for each of these hypotheses has
been presented by a number of groups, to date it has not been possible to probe protein-water
interactions in amorphous solids directly, and so only indirect evidence regarding water
replacement has been available

8-10.

To understand the interactions that control protein

conformation and stability in amorphous solids, a method to directly detect both protein-matrix and
protein-water interactions in lyophilized solids is needed.

Current methods used to characterize protein structure in lyophilized solids cannot detect these
interactions and lack structural resolution. For example, differential scanning calorimetry (DSC) is
used to study the thermal stability of lyophilized protein formulations based on the glass transition
temperature (Tg), while Fourier-transform infrared (FTIR) spectroscopy has been used to determine
protein secondary structure. Although these methods are used to compare formulations, their lowresolution and lack of detailed structural information are inherent limitations. Moreover, Tg is a bulk
measure and does not always correlate with protein stability, since degradation mediated by local
fluctuations and residual water can occur at temperatures below Tg 11, 12. High-resolution methods
such as nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography are not
generally applicable to amorphous samples, since they require large amounts of sample with some
long-range order and/or isotopic labeling. In addition, FTIR and NMR generate ensemble-averaged
spectra that usually cannot distinguish sub-populations containing different protein conformers.
Thermogravimetric analysis (TGA) and Karl-Fischer titration have been used to determine the bulk
water content of the formulation, but cannot identify the local distribution of hydration within a
protein molecule or spatial differences in this distribution in the sample as a whole.
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To provide higher resolution structural information on proteins in lyophilized solids, our group has
developed solid-state hydrogen deuterium exchange with mass spectrometric analysis (ssHDXMS) and applied it successfully to analyze protein conformation in lyophilized powders, achieving
peptide-level resolution. ssHDX-MS is able to distinguish the effects of different formulation
excipients on structure in lyophilized solids

13, 14,

and, in a recent study of lyophilized myoglobin

formulations, provided significantly higher correlation with aggregation during storage than FTIR 15.
ssHDX-MS is not without its limitations, however. As in solution HDX, loss of the deuterium label
due to back-exchange occurs rapidly for side-chain functional groups, so that only the exposure of
the peptide backbone can be probed. Back exchange also necessitates rapid analysis of
deuterated samples.

To address these limitations, we have developed a complementary approach to ssHDX-MS called
solid-state photolytic labeling- mass spectrometry (ssPL-MS) 16. This method utilizes a photoactive
reagent such as photo-leucine (pLeu; L-2-amino-4, 4'-azipentanoic acid) as an excipient and an
external probe. UV irradiation of the freeze-dried solid activates the probe, leading to covalent
labeling of matrix-accessible protein side-chains. Unlike ssHDX-MS, there are no constraints with
respect to experimental conditions (pH, temperature) as the pLeu label is stable and does not
undergo back-exchange. Using this method, we studied excipient effects on protein side-chain
environment with peptide-level resolution16.

Building on those findings, the studies reported here present a new approach to interrogating
protein interactions in amorphous solids based on photolytic crosslinking. Photolytic crosslinking
has been widely used in molecular biology to study protein-protein interactions in living cells

17-19,

and is adapted here to a condensed phase. In this approach, termed solid-state photolytic crosslinking with mass spectrometric analysis (ssPC-MS), a heterobifunctional crosslinking reagent (e.g.
succinimidyl 4, 4’- azipentanoate; SDA) is first used to derivatize reactive side chains in the protein
of interest (Appendix, Fig. A2). Following lyophilization and exposure of the powder to UV light of
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a certain wavelength, a covalent bond is created between the derivatized side chain and another
nearby molecule in the solid matrix. After reconstitution, the crosslinked protein is analyzed by LCMS at the intact level, or digested enzymatically prior to LC-MS analysis to assess the number and
type of adducts formed and to identify the different interactions experienced by particular proteolytic
fragments. Alternatively, the reactive side chain may be engineered into the protein sequence, e.g.,
using photoactive amino acid derivatives such as pLeu. The length of the crosslinker can be varied
by changing the length of the spacer arm, allowing the environment at different distances from the
protein side chain to be probed.

ssPC-MS is similar to ssPL-MS in that both use photolytic reactions and hence are amenable to
the solid state, in contrast to solution-state labeling reagents that are pH-sensitive. In ssPL-MS, the
photoactive functional group is part of an excipient in the solid matrix, while in ssPC-MS the
photoreactive functional group is incorporated onto protein side chains (Appendix, Fig. A3). ssPLMS reactions are carried out in a single step while crosslinking with a heterobifunctional reagent
requires two-step activation. Matrix-accessible side-chains are derivatized by covalent labeling,
whereas crosslinking results in covalent linking of a side-chain with any matrix component such as
protein, water or excipient. Thus labeling provides information about structural changes and matrix
accessibility at the side-chain level whereas crosslinking advances this method by providing direct
information about the microenvironment of a side-chain. The labeling reagent photo-leucine and
the crosslinker SDA both contain a photoactive diazirine ring that is activated at 350-365 nm and
forms a reactive singlet carbene (Appendix, Fig. A1). The carbene can undergo internal conversion,
insert into any X-H bond (X= C, O, N, S) or add on to a C=C bond, forming covalent adducts with
species within the distance of the spacer arm, including water, formulation additives (e.g. raffinose)
and other protein molecules

20.

ssPC-MS and ssPL-MS are similar to ssHDX-MS in that all three

techniques label the protein and reflect protein conformation in the solid state. The methods differ
in that ssPC-MS and ssPL-MS map the interactions of protein side-chains with the surrounding
matrix, while ssHDX-MS probes protein backbone conformation and dynamics. Unlike ssHDX-MS,
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the labeling reactions of ssPC-MS and ssPL-MS are irreversible and so are not subject to the backexchange that occurs in ssHDX-MS and other hydrogen-deuterium exchange methods.

To evaluate the utility of ssPC-MS, we used the heterobifunctional crosslinker SDA (spacer arm
length 3.9 Å) to derivatize equine myoglobin (Mb) in various formulations. Crosslinking with SDA is
a two-step process. In the first step, a succinimidyl ester is activated in solution at pH 6-9 and reacts
with available primary amines in the protein, usually Lys side chains and the N-terminus. Following
lyophilization, the photoactive diazirine group of SDA is activated by exposing the solid powder to
UV-A light at 365 nm, resulting in the loss of N2 and the formation of a reactive carbene. The
carbene inserts into any X-H bond (X= C, O, N, S) or adds on to a C=C bond, forming covalent
adducts with species within the distance of the spacer arm, including water, formulation additives
(e.g. raffinose) and other protein molecules. Based on the number of peptide-peptide, peptidewater and peptide-excipient adducts, the microenvironment of derivatized protein side chains was
characterized with high resolution. Importantly, SDA labeling and ssPC-MS provided direct
evidence for the perturbation of protein structure in the solid state and provided support for regional
water-replacement in lyophilized protein-carbohydrate systems.

3.3

MATERIALS AND METHODS

Holo-myoglobin from equine skeletal muscle (Mb), potassium phosphate monobasic and dibasic,
Tris base, D-(+)-raffinose pentahydrate, guanidine hydrochloride (Gdn) and anhydrous dimethyl
sulfoxide (DMSO) were purchased from Sigma Aldrich (St. Louis, MO). The heterobifunctional
crosslinker succinimidyl 4,4'-azipentanoate (SDA) was obtained from Thermo Scientific (Rockford,
IL). Trypsin was obtained from Promega (Madison, WI) and mass spectrometry-grade water,
acetonitrile and formic acid from Fisher Scientific (Fair Lawn, NJ).
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3.3.1

Sample Preparation

Mb was dissolved in potassium phosphate buffer (2.5 mM, pH 7.4) and dialyzed using cellulose
ester tubing (MWCO 8-10 kDa, Spectrum Laboratories, Rancho Dominguez, CA) against the same
buffer for 24 h. The dialyzed protein stock solution was filtered through a 0.22 µm syringe filter
(Gelman Nylon Acrodisc 13) and the protein concentration measured by visible spectroscopy
(extinction coefficient ε555nm = 12.92 mM-1cm-1). This stock solution was used for further experiments.
Stock solutions for raffinose and Gdn (3 M) in potassium phosphate buffer (2.5 mM, pH 7.4) were
prepared, filtered through a 0.22 µm syringe filter and stored at 4 °C until use. A 10 mM stock
solution of SDA in DMSO was prepared and stored away from light at room temperature.

3.3.2

Labeling Mb with SDA in Solution

To covalently link the SDA label to Mb via the NHS group, stock solutions of Mb and SDA were
mixed such that the protein: SDA molar ratio was 1:10 (final SDA concentration 0.39 mM). The
mixture was allowed to stand at room temperature in the dark for 15 min followed by quenching
with Tris HCl (100 mM final concentration, pH 8.0). The labeled protein sample (hereinafter referred
to as Mb-SDA) was desalted using a spin desalting column (MWCO 7 kDa; Thermo Scientific,
Rockford, IL) to remove excess unreacted SDA. The desalted Mb-SDA solution was stored at 4 °C
and used for crosslinking experiments.

3.3.3

Structural Integrity of Labeled Protein

Far-UV CD spectroscopy was used to determine the effect of SDA labeling on protein secondary
structure. Unlabeled and SDA-labeled Mb samples (Mb labeled with 10x molar excess of SDA;
0.39 mM SDA) were diluted to 3.6 µM and molar ellipticity measured on a JASCO J-815
spectrometer (JASCO Analytical Instruments, Easton, MD) in a 0.1 cm path length quartz cuvette.
Spectra were acquired from 180 nm to 260 nm at a scanning speed of 50 nm/min. Structural
integrity was also monitored by measuring the extent of protein modification as a function of SDA
concentration

21.

Mb was labeled with varying concentrations of SDA (0.05, 0.1, 0.26, 0.51, 0.77
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and 1.02 mM) for 15 min. The reaction was quenched with Tris HCl as above and the samples
diluted to 20 pmol protein for LC-MS analysis. The fraction of each labeled species was calculated
from the respective peak heights in the extracted ion chromatogram (EIC):

FL, i =

(Peak height)L, i

∑10
𝑖𝑖=0(Peak height)L,i

Equation 3.1

where FL, i is the fraction of protein containing i SDA labels (i = 0,1,…,10), the numerator is the peak
height for protein containing i SDA labels and the denominator is the sum of peak heights for
unlabeled protein (protein remaining unlabeled after quenching the labeling reaction; i = 0) and
labeled protein (i = 2,…,10). The concentrations of each labeled species (PL, i) were calculated by
multiplying FL, i by the initial protein concentration (P0).

PL, i = P0FL, i

Equation 3.2

The concentrations of unlabeled protein (P) and unused SDA remaining after quenching the
labeling reaction (X) were calculated as follows:

P = P0FL, i=0

Equation 3.3

𝑋𝑋 = X0 − ∑10
𝑖𝑖=1 𝑖𝑖PL, i

Equation 3.4

where P0 is the initial protein concentration and X0 is the initial SDA concentration. To test whether
the labeling reaction is second order, the natural logarithm of the ratio (PX0/P0X) was plotted against
X0 to detect any deviation of the slope (second order rate constant) from linearity.
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3.3.4

Lyophilization and Crosslinking in the Solid State

Stock solutions of Mb-SDA and raffinose were mixed such that the protein: raffinose ratio was 1:3
w/w (Table 3.1). A second formulation containing Mb-SDA and Gdn was prepared with a final
concentration of 1.5 M Gdn (Table 3.1). The formulations were lyophilized as described previously16.
Briefly, samples were lyophilized in borosilicate clear glass vials according to the following cycle:
loading samples on shelves precooled to -2 °C, freezing at -40 °C for 50 min (shelves precooled to
-2 °C), followed by drying under vacuum (70 mTorr) over 5 steps (-35 °C for 10 h, -20 °C for 8 h, 5 °C for 6 h, 10 °C for 6 h and 25 °C for 6 h). Lyophilized samples were stored at -20 °C until use.
Unlabeled Mb (Mb without SDA labeling) and Mb-SDA were formulated and lyophilized separately
and used as controls.

Table 3.1. Composition of lyophilized formulations.
% w/w
Lyophilized Formulation

a Mb,

Mb a

SDAa

Buffer

Excipient

Mb-SDA (10x) b

60.6

0.7

38.7

N/A

Mb-SDA (10x) + Raffinose (1:3 w/w)

21.5

0.2

13.7

64.5

Mb-SDA (10x) + Gdn a (1.5 M)

0.18

0.03

0.27

99.53

myoglobin; Gdn, guanidine hydrochloride; SDA, succinimidyl 4,4'-azipentanoate.

b Mb-SDA

(10x) denotes Mb labeled with 10x molar excess of SDA in solution.

The samples were tested for SDA-labeling-induced structural perturbations of Mb secondary
structure in lyophilized powders. Solid-state Fourier transform infrared (ssFTIR) spectroscopy was
carried out for the unlabeled and SDA-labeled samples using a Tensor 37 spectrometer (Bruker
Optics, Billerica, MA) as described previously13. The moisture content of the SDA-labeled Mb
formulations was determined using a gravimetric analyzer (Q5000SA; TA Instruments, New Castle,
DE). The humidity chamber was equilibrated to 0 % RH at 50 ˚C. Approximately 1-2 mg of the

55
lyophilized powder was loaded onto the platinum sample pan and exposed at 50 ˚C, 0 % RH for 2
h, with data acquisition at 4 s intervals.

Crosslinking was initiated by irradiating the freeze-dried samples at 365 nm for 30 min using a UV
Stratalinker 2400 (Stratagene Corp., La Jolla, CA) as described previously16. The irradiated
samples were reconstituted in 200 µL ammonium bicarbonate (100 mM, pH 8.0) and stored at 4 °C
until further use. For intact protein analysis using LC-MS, the reconstituted samples were diluted
to 20 pmol protein with MS water containing 0.1 % formic acid.

3.3.5

Digestion of Crosslinked Protein

Mb-SDA crosslinked in the presence or absence of excipients in the solid state was reconstituted
with 200 µL ammonium bicarbonate (100 mM, pH 8.0) and digested with trypsin (1:10 molar ratio
of trypsin to protein) at 60 °C for 16 h, then quenched with MS water containing 0.1 % formic acid.
Solution controls were prepared for all three formulations and were digested similarly after
crosslinking in solution.

3.3.6

Mass Spectrometry

Labeled and crosslinked solid- and solution-state samples were analyzed using an HPLC-MS
system equipped with an ESI source (1200 series HPLC, 6520 qTOF; Agilent Technologies, Santa
Clara, CA). Tryptic peptides (SDA-labeled and unlabeled) and peptide adducts were separated on
a ZORBAX SB-C18 column (Agilent Technologies; 1.0 x 50 mm, particle size 3.5 µm) using a
gradient, as described previously16. MS/MS was performed on selected peptides labeled with SDA
(Appendix, Table A3). The peptides were fragmented using CID (13 V) and the product ions
analyzed using MassHunter software.
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3.3.7

Data Analysis

The software package GPMAW (Version 9.21b3, Lighthouse Data, Odense, Denmark) was used
to generate a list of theoretical masses for peptide-peptide adducts. Information regarding the
protein (amino acid sequence from UniProtKB P68082), enzyme (trypsin; up to 4 missed cleavages)
and crosslinker SDA (heterobifunctional; MW of the crosslinking spacer arm (C5H6O) 82.042 Da,
amine to carboxylic acid specificity) was created in the software. Two other lists were prepared
manually for peptide-raffinose and peptide-water adducts. Up to four missed cleavages with trypsin
and up to four SDA labels per peptide (with up to four raffinose or water adducts, correspondingly)
were considered, along with dead-end modifications (SDA-N2), in which N2 is lost without the
formation of an adduct. The theoretical masses were compared with observed masses using
MassHunter software (Agilent Technologies, Santa Clara, CA) to detect peptide-peptide, peptideexcipient and peptide-water adducts. To compare excipient effects quantitatively, peptide-peptide,
peptide-water and peptide-excipient adducts were counted for each formulation. Local changes in
protein-matrix interactions were quantified by calculating peptide ‘crosslinking numbers’, described
in detail below.

3.3.7.1

Data Analysis for Crosslinking Numbers (X1n)

45 overlapping peptides were found to be involved in peptide-peptide adducts (refer below, section
‘Data Analysis for Qualitative Matrices). To compare local excipient effects quantitatively,
overlapping peptides were assigned to 8 groups, roughly corresponding to their position in the
amino acid sequence (Table 3.2). The peptide-peptide adducts obtained for peptides in each group
were counted and summed together to obtain a ‘crosslinking number’ for that group. The identity
of the crosslinking partner peptide was not considered; instead all partner peptides obtained after
crosslinking were considered in counting the number of adducts. Statistical analyses were
performed using OriginPro (Version 8.6, OriginLab, Northampton, MA) to compare crosslinking
numbers (1) between groups within the same formulation and (2) for the same group across
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formulations. Crosslinking numbers were also obtained for peptide-water and peptide-excipient
adducts for all 8 groups and compared statistically.

The number of SDA labels varied from 1 to 4 for tryptic peptides (see Results). This may give rise
to artifacts in crosslinking numbers, since peptides carrying more SDA labels are expected to
crosslink with multiple partners, giving artificially high crosslinking numbers for some groups. To
avoid this bias, crosslinking numbers for each group were normalized by dividing by the average
number of SDA labels (n) in the group (Table 3.2), calculated as follows:

[(1)(number of peptides with 1 SDA) + (2)(number of peptides with 2 SDA)
+ (3)(number of peptides with 3 SDA) + (4)(number of peptides with 4 SDA)]
𝑛𝑛 =
(Total number of labeled peptides (with 1 − 4 SDA) in the group)
A second bias may arise due to the number of tryptic peptides in each group. Groups with more
peptides will generate larger crosslinking numbers, as the crosslinking number is a sum of the
number of adducts obtained for all peptides within a group. For example, Group 1 has 1 tryptic
peptide while Group 4 has 15 peptides (Table 3.2). Hence a larger crosslinking number for Group
4 may not necessarily reflect more interactions, but may simply be a result of the number of
peptides within the group. Crosslinking numbers were therefore normalized a second time by
dividing by the number of tryptic peptides in each group (Table 3.2).

The “peptide crosslinking number” is defined as the number of chemically distinct adducts detected
between that peptide and another peptide fragment, water and/or raffinose. Peptide crosslinking
numbers are specific to a particular peptide fragment and do not represent the total number of
adducts in the protein as a whole. For a particular group (Table 3.2), the number of unique adducts
detected (i.e. sum of peptide crosslinking numbers for all peptides included within the group) is
summarized in the “group crosslinking number”, X1n. Here, the subscripts n=1, 2, 3 indicate peptidepeptide (X11), peptide-water (X12) and peptide-raffinose (X13) adducts, respectively. Peptides
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crosslinked by up to 4 SDA labels are included, as described above. The parameter X11
encompasses all peptide-peptide adducts formed for peptides within a group without regard to the
identity of the binding partner. For example, the following crosslinked peptide-peptide adducts were
detected for Group (3) (Table 3.2) in the absence of excipients: (Leu32-Lys45) x (Lys63-Lys77), (Leu32Lys47) x (Ala57-Lys62) and (Leu32-Lys47) x (Ala57-Lys63). Hence the peptide-peptide crosslinking
number (X11) for Group (3) is 3. This group also formed the following peptide-water adducts in the
absence of excipients: Leu32-Lys47 + 3SDA + 2H2O and Leu32-Lys45 + 4SDA + H2O (NB: The
reaction of diazirine with water occurs with loss of nitrogen (-N2) and may or may not include deadend modifications, so product masses are reduced accordingly). Hence the peptide-water
crosslinking number (X12) for Group (3) is 2. X1n values were normalized by dividing by the average
number of SDA labels in each group and by the number of tryptic peptides in each group, as
described above. This normalized value is denoted as X1n*.
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Table 3.2. Classification of peptides based on trypsin digestion pattern.
Amino

Number of

Tryptic

trypsin

Peptides

cleavage sites

included

Number of
Group

Acids

Secondary

SDA labels a
Included

Structure Elements

1

1-16

1

1

Gly1-Lys16

N-terminus, Helix A

2

17-31

2.5

1

Val17-Arg31

AB loop, Helix B

Leu32-Lys42,
Helix B, BC loop,
3

32-47

1.5

3

Leu32-Lys45,
Helix C, CD loop
Leu32-Lys47
Phe43-Lys45,
Phe43-Lys47,
Phe43-Lys50,
Phe43-Lys56,
Phe43-Lys62,
Phe46-Lys50,
Phe46-Lys56,
CD loop, Helix D,

4

43-63

2

6

Phe46-Lys62,
DE loop, Helix E
His48-Lys56,
His48-Lys63,
Thr51-Lys56,
Thr51-Lys62,
Thr51-Lys63,
Ala57-Lys62,
Ala57-Lys63
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Table 3.2. Classification of peptides based on trypsin digestion pattern (continued).
Lys63-Lys77,
5

63-79

1.3

4

Lys63-Lys78,

Helix E, EF loop

Lys63-Lys79
Lys78-Lys79,
Lys78-Lys87,
Lys78-Lys98,

6

78-98

1.4

Lys79-Lys87,

Helix E, EF loop,

Lys79-Lys96,

Helix F, FG loop

5
Gly80-Lys87,
Gly80-Lys96,
Pro88-Lys98
His97-Lys102,
His97-Lys118,

7

97-118

1.2

FG loop, Helix G

3
Ile99-Lys118,
Tyr103-Lys118
His119-Lys133,
His119-Arg139,
Ala134-Arg139,
Ala134-Lys145,

8

119-153

2

Ala134-Lys147,

GH loop, Helix H,

Asn140-Lys145,

C-terminus

4
Asn140-Lys147,
Asn140-Gly153,
Tyr146-Gly153,
Gln148-Gly153
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a

Average number of SDA labels per group (n) was calculated as described in Materials and

Methods.

3.3.7.2

Data Analysis for Qualitative Matrices

At the Mb-SDA digest level, 100 non-redundant overlapping peptides labeled with 0-4 labels were
detected (72 labeled and 28 unlabeled). Due to matrix heterogeneity arising from variable SDAlabeled populations, promiscuity of the reactive carbene and the amorphous nature of lyophilized
solids, considering only non-overlapping peptides may result in loss of information regarding the
adducts present. Hence, all overlapping peptides were included in the analysis. Since the
crosslinked species differ in abundance and ionization efficiencies, and since authentic standards
of the more than 100 crosslinked species produced were not available, the crosslinked adducts
formed in the solid state were not quantified. Instead, a qualitative approach was used to describe
the detectable interactions of the protein in lyophilized formulations. Theoretically, each of the 72
labeled peptides can crosslink with any of the 100 non-redundant overlapping peptides upon
irradiation. Additional combinations are possible due to multiple dead-end modifications, and a
crosslinked adduct may contain more than 2 peptides if they are crosslinked by more than one SDA
molecule. The list for all such possible combinations is > 2.2 x 107 compounds. For simplicity, only
those adducts consisting of 2 peptides linked by 1 to 4 SDA were considered. For all three
formulations, 69-80 % of the peptide-peptide interactions involved crosslinking through 1 SDA, with
fewer adducts detected containing ≥ 2 SDA molecules. 45 overlapping tryptic peptides were found
to be involved in such peptide-peptide adducts and 44 overlapping tryptic peptides labeled with 1
to 4 SDA molecules were found to interact with water and raffinose and were selected for the matrix
(Fig. 4 and 5).

Peptide-peptide interactions for each formulation were mapped qualitatively as a symmetric matrix
showing the interactions detected in three replicate LC-MS injections (main text, Fig. 4). In the map,
color intensity indicates the number of injections (1, 2 or 3) in which a particular interaction was
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detected. An interaction was considered “detected” if one or more masses corresponding to the 2
peptides linked by 1 to 4 SDA was observed. Adducts detected in a single injection represent
crosslinking between multiple pairs of proteins. Repeat injections of the same sample did not
always give the same adducts, perhaps due to matrix heterogeneity, variable number of SDA labels
and/or low concentration of crosslinked species (Appendix, Fig. A7). For example, for Mb-SDA
crosslinked in the absence of excipients, the first injection produced 41 total peptide-peptide
adducts (including 16 adducts absent in the second and third injections), the second injection
produced 40 adducts (including 11 adducts absent in the first and third injections) while the third
injection produced 37 adducts (including 6 adducts absent in the first and second injections). An
average of 54-67 % of the adducts were observed in all three injections for all formulations. Similar
maps showing the maximum number of SDA linkages (1, 2, 3 or 4), maximum number of water
molecules (1, 2, 3 or 4) and maximum number of raffinose molecules (1) in each adduct after a
single injection are provided in SI (Appendix, Fig. A5 and A6).

45 overlapping peptides were found to be involved in peptide-peptide adducts (see Results). To
compare local excipient effects quantitatively, overlapping peptides were assigned to 8 groups,
roughly corresponding to their position in the amino acid sequence (Table 3.2). The peptide-peptide
adducts obtained for peptides in each group were counted and summed together to obtain a
‘crosslinking number’ for that group. The identity of the crosslinking partner peptide was not
considered; instead all partner peptides obtained after crosslinking were considered in counting the
number of adducts. Statistical analyses were performed using OriginPro (Version 8.6, OriginLab,
Northampton, MA) to compare crosslinking numbers (1) between groups within the same
formulation and (2) for the same group across formulations. Crosslinking numbers were also
obtained for peptide-water and peptide-excipient adducts for all 8 groups and compared statistically.

The number of SDA labels varied from 1 to 4 for tryptic peptides (see Results). This may give rise
to artifacts in crosslinking numbers, since peptides carrying more SDA labels are expected to
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crosslink with multiple partners, giving artificially high crosslinking numbers for some groups. To
avoid this bias, crosslinking numbers for each group were normalized by dividing by the average
number of SDA labels (n) in the group (Table 3.2), calculated as follows:

[(1)(number of peptides with 1 SDA) + (2)(number of peptides with 2 SDA)
+ (3)(number of peptides with 3 SDA) + (4)(number of peptides with 4 SDA)]
𝑛𝑛 =
(Total number of labeled peptides (with 1 − 4 SDA) in the group)
A second bias may arise due to the number of tryptic peptides in each group. Groups with more
peptides will generate larger crosslinking numbers, as the crosslinking number is a sum of the
number of adducts obtained for all peptides within a group. For example, Group 1 has 1 tryptic
peptide while Group 4 has 15 peptides (Table 3.2). Hence a larger crosslinking number for Group
4 may not necessarily reflect more interactions, but may simply be a result of the number of
peptides within the group. Crosslinking numbers were therefore normalized a second time by
dividing by the number of tryptic peptides in each group (Table 3.2).

3.4
3.4.1

RESULTS

Intact Protein Labeling with SDA

Following initial succinimidyl derivatization, Mb-SDA carrying up to five labels was detected by LCMS (Fig. 3.1). No significant secondary structural changes after SDA-labeling were detected using
CD spectroscopy (Fig. 3.2A) and solid-state FTIR spectroscopy (Appendix, Fig. A4). However, this
does not preclude any tertiary structure changes that may have occurred but were undetected by
CD and FTIR. The relationship between the ratio (PX0/P0X) and SDA concentration (X) was
consistent with second-order kinetics up to 0.51 mM SDA (Fig. 3.2B), further indication that minimal
structural perturbation is induced by SDA labeling below this value. All further experiments were
performed using a 10:1 ratio of SDA to protein with SDA concentrations below 0.51 mM to minimize
effects of labeling on protein structure.
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Figure. 3.1. Deconvoluted mass spectrum of Mb labeled with 10x molar excess of SDA (0.39 mM
SDA). Up to 5 labeled species were detected. Inset: Deconvoluted mass spectrum of Mb without
SDA labeling.

Figure 3.2. (A) Far-UV CD spectra of Mb without SDA labeling (dotted line) and Mb labeled with
10x molar excess of SDA (solid line) (B) Dose-response curve for Mb labeled with varying
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concentrations of SDA. [P], protein remaining unlabeled after quenching the labeling reaction; [P0],
initial protein concentration; [X], SDA remaining unused after quenching the labeling reaction; [X0],
initial SDA concentration. The plot shows linearity up to 0.51 mM SDA (no deviation of the second
order rate constant) indicating minimal perturbation of tertiary structure.

3.4.2

Peptide-Level Labeling with SDA

LC/MS analysis with proteolytic digestion was conducted to identify the sites of attachment of the
SDA to Mb via an NHS-linkage. Digestion of Mb-SDA yielded a total of 72 overlapping labeled
tryptic fragments that provided complete sequence coverage (Fig. 3.3). LC-MS/MS analysis
conclusively established that labeling occurred on the N-terminal Gly1, Lys42, Lys50, Lys56, Lys87
and Lys147, consistent with the accepted reaction mechanism and with preferential labeling at
primary amines by NHS esters at pH 7.4. In the peptides selected for MS/MS analysis, labeling
was not detected on Lys16, Lys77, Lys78, Lys79, Lys96 and Lys118. For the other labeled peptides, the
site of labeling could not be identified definitively at the amino-acid level due to low abundance and
insufficient b- and y-ions. Interestingly, the peptide Asn140-Lys147 showed 4 SDA labels, although it
contains only two Lys. Similarly, peptides Val17-Arg31 (containing no Lys), His119-Lys133 (one Lys)
and Ala57-Lys63 (two Lys) each carried up to four SDA labels. This suggests that SDA does not
label primary amines exclusively, but shows some reactivity towards other residues, as reported
previously for Ser and Tyr with NHS esters 22, 23.
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Figure 3.3. Amino acid sequence of Mb showing the domain organization with white cylinders
representing the α-helices. Solid bars represent the tryptic peptides labeled with one SDA (white);
two SDA (light grey); three SDA (dark grey) and four SDA (black).

3.4.3

Crosslinking in the Solid State

Mb-SDA irradiated in the solid state (with and without excipients) and digested with trypsin showed
peptide-peptide, peptide-water and peptide-excipient adducts, as indicated by comparing the
theoretical masses with the masses observed on LC-MS. The theoretically possible peptide-water
and peptide-excipient adducts are listed in Table A4 (Appendix), allowing for a maximum of four
SDA labels per tryptic peptide and up to four missed cleavages. A qualitative approach was used
to describe the detectable interactions of the protein in lyophilized formulations. The criteria used
for peptide selection and associated variability are described in Materials and Methods (refer
section ‘Data Analysis For Qualitative Matrices’). Peptide-peptide adducts linked by up to 4 SDA
for each formulation were mapped qualitatively as a symmetric matrix showing the interactions
detected in three replicate LC-MS injections (Fig. 3.4). In the map, color intensity indicates the
number of injections (1, 2 or 3) in which a particular interaction was detected. An interaction was
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considered “detected” if one or more masses corresponding to the 2 peptides linked by 1 to 4 SDA
was observed. The adducts detected in a single injection represent crosslinking between many
pairs of protein molecules.

Intermolecular peptide-peptide adducts were detected throughout the Mb sequence in all
formulations (Fig. 3.4). The crosslinking reaction is not expected to favor a particular amino acid,
since the photoactive diazirine generates a singlet alkyl carbene that reacts non-specifically with
X-H groups (X = C, N, O, S) or C=C bonds on exposure to UV-A light 24. In the absence of excipient
(‘control formulation’), adducts involving the CD, DE and EF loops and helix H were common, as
shown in horizontal and vertical bands near the center and edge of the map (Fig. 3.4A). In
formulations containing raffinose, adducts were more distributed than in the control formulation as
shown by the spread of colored boxes in the matrix (Fig. 3.4B). In the Gdn HCl formulation, the
map shows a number of interactions not detected in the control and raffinose formulations (Fig.
3.4C), consistent with unfolding and increased molecular contacts.

We infer that the peptide-peptide adducts for the control and raffinose formulations are
intermolecular, since the calculated distance between the peptides in the crystal structure is greater
than the length of the NHS spacer arm (3.9 Å) (PDB ID 1WLA; PyMOL Molecular Graphics System,
Version 1.3, Schrödinger LLC). Although secondary structure changes in the control and raffinose
formulations were not detected by CD and FTIR spectroscopy, it is possible that some
intramolecular crosslinking may also have occurred as the result of tertiary structure perturbation.
For the Gdn HCl formulation where the protein concentration (< 1% w/w) was low relative to the
amount of Gdn HCl (~99% w/w) in the solid-state, the protein is considered to be fully denatured.
At such a high excipient-to-protein ratio, it is likely that peptide-peptide adducts are the result of
intramolecular interactions. However, intramolecular and intermolecular adducts cannot be
definitively distinguished in the present work.
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Figure 3.4. Peptide-peptide adducts formed in (A) Mb-SDA alone (control), (B) Mb-SDA with
raffinose and (C) Mb-SDA with Gdn HCl formulations. Peptide-peptide adducts detected in
single (■), duplicate (■) and triplicate (■) sample injection(s) are plotted. Adducts were mapped
irrespective of the number of SDA linkages (1-4 SDA). The

-helices from N-terminus to C

terminus in Mb are represented by cylinders labeled A to H respectively.
*The molecular mass of tryptic fragments 63-77 and 64-78, 63-78 and 64-79 are identical and
cannot be differentiated. The molecular mass for peptide-peptide adducts (32-45 x 43-47) and
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(32-47 x 43-45); (79-87 x 51-63) and (78-87 x 51-62); (63-78 x 57-63) and (63-79 x 57-62) are
identical and cannot be differentiated.

Peptide-water (and peptide-raffinose) adducts were mapped similarly for each formulation (both in
solid- and solution state), by considering up to 4 water or raffinose molecules crosslinked with a
peptide via up to 4 SDA (Fig. 3.5 and Fig. A6 in Appendix). 40 overlapping tryptic peptides labeled
with 1 to 4 SDA molecules were found to interact with water and raffinose and were selected for
the matrix. Peptide-water adducts were distributed across the entire molecule for all three
formulations. Qualitative differences were observed, with several adducts detected only in the Gdn
HCl formulation (Fig. 3.5, columns E and F). Peptide-water adducts across helices D and E were
fewer in the raffinose formulation (both solid and solution-state) than in the control and Gdn HCl
formulations (columns C and D). Fewer peptide-raffinose adducts were detected for the solid-state
formulation than in solution (columns G and H). Only raffinose adducts, and not raffinose
pentahydrate, were detected. Peptide-Gdn adducts, although detected, are not reported since their
masses could not be distinguished from those of some unlabeled peptides and their abundance
was not sufficient to provide definitive MS/MS fragmentation patterns.

3.4.4

Total Number of Adducts

The total numbers of chemically distinct peptide-peptide, peptide-water and peptide-excipient
adducts detected in lyophilized and solution-state formulations were counted and averaged across
triplicate LC-MS injections (Table 3.3). The solid-state formulations showed significantly more
peptide-peptide adducts than in solution (p < 0.05), with the maximum number observed in the
presence of Gdn HCl. The number of peptide-water adducts was significantly greater (p < 0.05) in
the solid state than in solution for the control and Gdn HCl formulations, but was less than in solution
for the lyophilized raffinose formulation. The number of peptide-raffinose adducts in the solid state
was also significantly lower than in solution. Comparing the number of peptide-peptide adducts
across the three lyophilized formulations, the control and raffinose formulations were not
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significantly different from one another, whereas the numbers of peptide-water adducts across the
three lyophilized formulations were significantly different (p < 0.05).

Within the control formulation, the number of peptide-peptide adducts was similar to the number of
peptide-water adducts in both solution- and solid state. In the presence of raffinose, more peptidepeptide interactions were formed than peptide-water and peptide-raffinose interactions in the solid
state, whereas more peptide-raffinose adducts were formed in solution. In the presence of Gdn
HCl, the number of peptide-water adducts was slightly greater than peptide-peptide adducts in
solution, but decreased in the solid state.

Table 3.3. Total number of peptide-peptide, peptide-water and peptide-excipient adducts detected
by LC-MS in solid- and solution-state Mb-SDA formulations without excipients, with raffinose and
with Gdn HCl. The numbers represent the average number of adducts (± SD) from three LC-MS
injections.
Number of Adducts Detected
Type of Adducts

a

Mb-SDA

Mb-SDA + Raffinose

Mb-SDA + Gdn HCl

Solid

Solution

Solid

Solution

Solid

Solution

Peptide-Peptide

44.7 ± 3.5

30.3 ± 0.6

50.7 ± 3.2

31.3 ± 1.2

105.0 ± 12.3

28.3 ± 2.1

Peptide-Water

42.7 ± 3.8

30.0 ± 1.7

11.3 ± 1.2

19.7 ± 1.2

74.3 ± 10.2

34.3 ± 1.5

Peptide-Excipient

N/A

N/A

11.3 ± 0.6

41.3 ± 0.6

N/A a

N/A a

Peptide-excipient adducts for the Gdn HCl formulation could not be identified unambiguously by

LC-MS and are not reported.

73

Figure 3.5. Tryptic peptides of Mb detected as peptide-water adducts in (A) lyophilized Mb-SDA,
(B) Mb-SDA solution, (C) Mb-SDA lyophilized with raffinose, (D) Mb-SDA solution with raffinose,
(E) Mb-SDA lyophilized with Gdn HCl and (F) Mb-SDA solution with Gdn HCl formulations. Tryptic
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peptides of Mb detected as peptide-raffinose adducts in (G) Mb-SDA lyophilized with raffinose and
(H) Mb-SDA solution with raffinose formulations. Peptide-water adducts detected in single (■),
duplicate (■) and triplicate (■) sample injection(s) and peptide-raffinose adducts detected in single
(■), duplicate (■) and triplicate (■) sample injection(s) are plotted. Adducts were mapped
irrespective of the number of water or raffinose molecules linked. The α-helices from N-terminus to
C-terminus in Mb are represented by cylinders labeled A to H respectively.
* The molecular mass of tryptic fragments 63-77 and 64-78; 63-78 and 64-79 are identical and
cannot be differentiated.

3.4.5

Peptide Crosslinking Numbers (X1n) and Formulation Effects

To summarize the data and allow meaningful inferences about formulation differences at the local
level, crosslinked peptides were assigned to 8 groups according to the overlapping tryptic
fragments obtained (Table 3.2). Peptide crosslinking numbers (X1n) were calculated as described
in Materials and Methods. Normalized X1n values (denoted X1n*) for each group were averaged
across triplicate LC-MS measurements and expressed as mean ± standard deviation. The X1n*
were compared: (1) across groups within a formulation and (2) within a group across formulations.
One-way ANOVA demonstrated that the number of peptide-peptide adducts (X11*), peptide-water
adducts (X12*) and peptide-excipient adducts (X13*) are significantly different across groups within
a given formulation (p < 0.05). Comparing X1n* values for a group across formulations (p < 0.05)
also showed significantly different means for all groups except Group (2) for X11*, based on Tukey’s
post-hoc analysis.

The crosslinking numbers can be used to compare interactions within and between formulations.
For the lyophilized formulation without excipients (control formulation), the sum of group X11* values
(denoted as ΣX11*) for Mb-SDA was 6.8 (± 1.7) (Table 3.4), a weighted measure of the total number
of distinct peptide-peptide adducts formed. Similarly, ΣX12*, the sum of X12* values for this
formulation was 6.8 (± 0.9) (Table 3.4), a weighted measure of the distinct peptide-water adducts
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formed. In this formulation, the greatest X11* values were observed for Groups (4), (6) and (8),
consistent with greater involvement in protein-protein interactions in these regions (Fig. 3.6A, white
bars). X11* values for these groups were significantly greater than values for the other groups.
Group (5) showed the greatest number of peptide-water adducts (X12*), while the remaining groups
did not show significantly different X12* values (Fig. 3.6B, white bars).

Table 3.4. Crosslinking numbers for peptide-peptide adducts (X11*) values (± SD, n=3) for each
lyophilized formulation.
X11* (± SD)
Group
Control

Raffinose

Gdn HCl

1

0.7 ± 0.6

1.7 ± 0.6

4.7 ± 0.6

2

0.4 ± 0.4

1.2 ± 0.4

1.6 ± 0.7

3

0.4 ± 0.2

0.9 ± 0.0

1.9 ± 0.3

4

1.0 ± 0.1

0.9 ± 0.1

2.6 ± 0.4

5

0.3 ± 0.6

0.8 ± 0.1

1.4 ± 0.1

6

1.8 ± 0.3

2.1 ± 0.3

3.4 ± 0.2

7

0.9 ± 0.2

0.4 ± 0.2

2.2 ± 0.3

8

1.2 ± 0.1

1.6 ± 0.2

2.6 ± 0.3

Total (ΣX11*)

6.8 ± 1.7

9.7 ± 1.5

20.5 ± 1.5
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Table 3.5. Crosslinking numbers for peptide-water adducts (X12*) values (± SD, n=3) for each
lyophilized formulation.

X12* (± SD)
Group
Control

Raffinose

Gdn HCl

1

0.3 ± 0.6

1.0 ± 0.0

2.0 ± 0.0

2

0.9 ± 0.2

0.4 ± 0.0

1.5 ± 0.2

3

0.4 ± 0.0

0.3 ± 0.1

1.4 ± 0.3

4

0.3 ± 0.1

0.0 ± 0.0

0.4 ± 0.1

5

3.3 ± 0.1

2.2 ± 0.5

2.9 ± 0.4

6

0.9 ± 0.1

0.4 ± 0.0

1.0 ± 0.4

7

0.3 ± 0.1

1.0 ± 0.0

1.1 ± 0.0

8

0.3 ± 0.3

0.2 ± 0.1

0.7 ± 0.1

Total (ΣX12*)

6.8 ± 0.9

5.6 ± 0.5

11.0 ± 1.0

Note: The moisture contents of the control, raffinose and Gdn HCl formulations were 1.03 %,
1.92 % and 0.04 % (w/w) respectively.

77

Table 3.6. Crosslinking numbers for peptide-raffinose adducts (X13*) values (± SD, n=3) for MbSDA lyophilized and crosslinked in the presence of raffinose.

a

Group

X13* (± SD)

1

0.0 ± 0.0

2

0.0 ± 0.0

3

0.1 ± 0.1

4

0.2 ± 0.0

5

0.1 ± 0.1

6a

0.2 ± 0.1

7

0.2 ± 0.0

8

0.2 ± 0.0

Total (ΣX13*)

1.9 ± 0.2

Note that Group (6) (spanning Lys78-Lys98) was expanded slightly to Lys79-Lys102 to accommodate

peptide Lys79-Lys102 that was found to form a raffinose adduct.

Figure 3.6. (A) Peptide-peptide adducts, (B) Peptide-water adducts and (C) Peptide-raffinose
adducts detected by LC-MS. White bars represent Mb-SDA lyophilized in the absence of excipients
(blank), grey bars represent Mb-SDA lyophilized with raffinose and black bars represent Mb-SDA
lyophilized with Gdn HCl. X1n values were counted for peptides assigned to 8 groups. Bars
represent mean normalized X1n values (X1n*) ± SD (n=3). Note that in the abscissa for panel (C),
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Group (6) spanning residues Lys78-Lys98 was expanded to Lys78-Lys102 to accommodate peptide
Lys79-Lys102 which was found to form raffinose adducts.

In the lyophilized raffinose formulation, ΣX11* was 43 % greater than the excipient-free control (Table
3.4, Fig. 3.7A, grey bars), consistent with an increase in the number of distinct peptide-peptide
adducts, although this was not a significant increase. ΣX12* for this formulation was 31% less than
control, consistent with fewer distinct peptide-water adducts (Table 3.5, Fig. 3.7B, grey bars). The
X12* values differed among the peptide fragment groups in the raffinose formulation (Table 3.5, Fig.
3.6B, grey bars). Group (5) again showed the greatest X12* value, while Groups (2), (3), (4), (6) and
(8) showed X12* values < 1.0. Various peptide-raffinose adducts were also detected in the solidstate, with the maximum X13* for Group (6) (Table 3.6, Fig. 3.6C).

Figure 3.7. Total number of peptide-peptide (A), peptide-water (B) and peptide-raffinose (C)
adducts observed for the protein in solution and solid-state (Mean ± SD (n=3)). White bars
represent solution-state adducts and black bars represent adducts observed in the lyophilized
formulation.

In the lyophilized Gdn HCl formulation, the ΣX11* value was 3 times greater than the control,
indicating more distinct peptide-peptide adducts (Table 3.3, Fig. 3.7A, black bars). ΣX12* for this
formulation was 1.6 times greater than the control, indicating more distinct peptide-water adducts
(Table 3.4, Fig. 3.7B, black bars). X11* values were greater than control for all groups except Group
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(2). Within the formulation, the maximum X11* values were observed for Groups (1) and (6), followed
by Groups (4) and (8) (Fig. 3.6A, black bars). X12* values were significantly greater than in the
control formulation for all groups except Groups (4), (5) and (6) (Fig. 3.6B, black bars). The overall
increase in X1n* values is consistent with protein unfolding (as confirmed by CD and FTIR
spectroscopy) and increased interactions with the matrix.

Comparing ΣX11* and ΣX12* values across lyophilized formulations, the numbers of peptide-peptide
and peptide-water interactions were significantly greater in the Gdn HCl formulation (Fig. 3.7A, B).
Comparing ΣX11* values across solution state formulations, peptide-peptide interactions were
significantly greater in the Gdn HCl formulation, while ΣX12* values were similar across all three
solution formulations (Fig. 3.7A, B). Comparing solution- and solid-state formulations, ΣX11* values
were greater in the lyophilized raffinose and Gdn HCl formulations than in the corresponding
solution formulations, while ΣX12* for lyophilized Gdn HCl formulation was significantly greater than
in the solution state. Peptide-raffinose adducts (ΣX13*) for the solution-state raffinose formulation
were significantly greater than in the solid state (Fig. 3.7C).

To determine the physical form of the excipient in the solid state, the lyophilized formulations were
examined using X-ray diffraction. The control and raffinose formulations remained amorphous while
the Gdn HCl formulation showed crystalline features, suggesting that the excipient had crystallized
(data not shown). To relate the formation of peptide-water adducts to overall moisture content, the
moisture content was determined using gravimetric analysis. The moisture contents of the control,
raffinose and Gdn HCl formulations were 1.03%, 1.92% and 0.04% (w/w), respectively (Appendix,
Fig. A8). The raffinose formulation showed the fewest peptide-water adducts (Table 3.4, Fig. 3.7B),
although it had the highest gravimetric water content. Conversely, the Gdn HCl formulation had the
lowest water content and the most peptide-water adducts.
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3.5

DISCUSSION

The results presented here demonstrate that ssPC-MS can be used to map the protein
microenvironment in lyophilized formulations with peptide-level resolution, providing information on
the interactions of protein side chains with water, excipients and other protein molecules. Methods
such as FTIR and DSC are routinely used to characterize lyophilized proteins, but provide only bulk
information for the protein or matrix as a whole.

ssPC-MS probes the protein side-chain

environment with high resolution at the local level, based on qualitative determination of the types
of adducts formed and quantitative crosslinking numbers (X1n). To our knowledge, this is the first
time that protein-protein and protein-matrix interactions have been mapped directly in the solid
state.

The interaction maps show specific protein-matrix interactions at the peptide level and reflect the
heterogeneous nature of the lyophilized matrix (Fig. 3.4 and 3.5, Appendix Fig. A5 and A6). Not all
theoretically possible adducts were observed, as shown by the white boxes in the interaction maps
(Fig. 3.4 and 3.5, Appendix Fig. A5 and A6). The distribution of the peptide-peptide adducts
(colored or shaded boxes) across the maps suggests that Mb molecules are oriented in the solid
matrix in several different ways, allowing different adducts to be formed with the same peptide.
Despite the lack of long-range order, there appear to be constraints in the control and raffinose
formulations that prevent the formation of many of the theoretically possible adducts (white boxes).
That these constraints are related to protein structure is supported by the presence of a greater
number of unique adducts in the Gdn HCl formulation.

The interactions detected by ssPC-MS provide additional information about protein structure and
environment in the solid matrix. For example, several peptide-peptide adducts were observed in
the control and raffinose formulations for peptides spanning the CD, DE and EF loop regions (Fig.
3.4A, B). Motions of loop regions are linked to conformational transitions involving the helices of
Mb25. It has been shown experimentally and computationally that the CD and EF loops of holoMb
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are especially flexible, allowing for efficient ligand binding26-28. This loop flexibility may result in
better protein-protein contacts in the solid state. Any disruption of the salt bridge between residues
Lys45 and Asp60 that normally stabilizes the DE link with the CD loop

29, 30

could also contribute to

increased loop mobility in lyophilized solids and make the loop regions more prone to interactions.

In contrast to the loop interactions, peptide-peptide adducts were rarely observed for helices A and
G in the control and raffinose lyophilized formulations. In the folding pathway of holoMb, helices A,
G and H fold first and form a stable molten globule core31, 32. This is followed by folding of helices
B, C, D, E and F and heme coordination in a hydrophobic pocket between helices E and F. The
structure of holoMb is further stabilized by interhelix contacts between helices B-G, B-E, G-H, F-H,
A-E and A-H25, 33. Here, limited crosslinking for helices A and G may be explained by persistence
of the molten globule in the solid state. However, helix H formed several peptide-peptide adducts
despite being part of the molten globule. Previous ssHDX-MS have shown loss of backbone
protection in helix H upon lyophilization15, which may result in increased crosslinking for helix H.
No peptide-peptide crosslinking was observed between helices B-G, B-E, G-H and A-E in the
control and raffinose lyophilized formulations (Fig. 3.4A, B), perhaps as a result of interhelix
interactions preserved in the solid state and the inability of the side-chains to participate in
crosslinking.

The results show that crosslinking provides high-resolution information about protein-matrix
interactions in both solution and solid state. While data matrices (Fig. 3.4 and 3.5) can be used to
qualitatively describe the type of adducts formed, the number of adducts (Table 3.3) can be used
as a simple metric to quantify the fraction of interactions with each matrix component. The number
of peptide-matrix adducts can be affected by events such as unfolding, phase separation and
aggregation. Similar numbers of peptide-peptide and peptide-water adducts in the control
formulation (Table 3.3) suggest that there is equal likelihood of protein-protein and protein-water
contacts in the absence of excipients, assuming similar carbene reactivity with protein and water.
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The presence of interacting excipients and the nature of the interaction is expected to alter the
number of adducts, as observed with raffinose and Gdn HCl (Table 3.3).

Low X11* and high X12* values for E helix in all the three formulations suggest that the side-chains in
this region interact primarily with water. HoloMb contains a distal His64 residue (helix E) in the hemebinding pocket; this residue is involved in modulating heme-ligand affinity by binding to water 34, 35.
This suggests that there is a hydration layer around helix E, in which may be responsible for the
high frequency of water adducts with helix E peptides. Interestingly, the sites (peptides) of raffinose
crosslinking were not coincident with the sites for water crosslinking, even in solution (Fig. 3.5; only
2 peptides Lys46-Lys56 and Lys63-Lys77/Lys64-Lys78 out of 22 showed crosslinking with both water
and raffinose). Such observations have implications regarding the water replacement hypothesis,
as discussed below. The effects of Gdn HCl on local protein structure could be established, as
observed by the increased peptide-peptide crosslinking in the solid state (Fig. 3.4C). That X11* and
X12* values for most groups were greater in the Gdn HCl formulation than in the other two is also
consistent with greater matrix exposure.

The water replacement hypothesis states that lyophilized proteins are stabilized by hydrogen bonds
to sugars and other excipients in the dried state, which replace the hydrogen bonds to water that
stabilize the structure in solution 36. Previous studies have tested this hypothesis by measuring the
extent of hydrogen bonding using the FTIR band area at 1583 cm-1, which corresponds to
carboxylate- hydrogen bonding8, 37. The band area was found to be smaller in proteins lyophilized
in the absence of carbohydrate excipients, but increased with increasing carbohydrate
concentration 8. Though FTIR results provide some support for the water replacement hypothesis,
ssPC-MS allows these interactions to be interrogated directly. The presence of peptide-water
adducts in all three formulations studied here confirms that residual water is present at the protein
surface after lyophilization (Fig. 3.5A-F). Overall peptide-peptide interactions increased in the solid
state for the raffinose and Gdn HCl formulations, compared to solution (Table 3.3, Fig. 3.7A). This
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is expected as a result of freeze-concentration and increased protein-protein contacts. The
magnitude of this increase in protein-protein contacts is greatest in the lyophilized Gdn HCl
formulation (Fig. 3.7A). This is in part due to protein unfolding and also a possible result of Gdn
HCl crystallization. In solution, Gdn HCl binds to proteins and promotes unfolding. This binding may
explain the absence of more peptide-water adducts in the solution Gdn HCl formulation (Table 3.3,
Fig. 3.7B), even though the protein is partially unfolded at 1.5 M Gdn HCl

38.

We hypothesize that

when Gdn HCl crystallizes, the SDA-labeled residues are free to crosslink with water molecules,
resulting in increased ΣX11* and ΣX12* in the solid state compared to solution.

Preferential exclusion of carbohydrates is known to occur in solution at concentrations ≥ 0.2 M
40.

39,

In this study, raffinose was present at a concentration of ~ 2 mM; in such a dilute solution, it is

unlikely that there is appreciable raffinose exclusion. Hence, increased molecular mobility and
diffusion in solution are more likely to contribute to the observed protein-raffinose crosslinking.
While peptide-peptide crosslinking was greater in the lyophilized raffinose formulation than in
solution (Table 3.3, Fig. 3.7B), peptide-raffinose adducts were fewer in the solid state than in
solution (Table 3.3, Fig. 3.7C). Although the reduced mobility in the solid state is expected to
produce a greater number of intermolecular contacts and crosslinked adducts, the observed results
may be due to raffinose micro-phase separation in the solid state or water replacement by raffinose
in the solid state. If hydrogen bonds between Mb and raffinose in the solid state indeed replaced
hydrogen bonds to water in solution, one would expect to observe new peptide-raffinose adducts
in the solid state that were not observed in solution. In addition, these new raffinose adducts should
be detected in peptides for which peptide-water adducts were observed in solution. Neither of these
was observed with SDA crosslinking in solution- and solid-state raffinose formulations. A 3:1 w/w
ratio of raffinose to protein translates to about 100 molecules of raffinose per protein molecule, so
that it is unlikely that the solid is too dilute in raffinose, at the bulk level, for reaction with SDA to
occur. Thus, water replacement is the less likely explanation for the peptide-water and peptide
raffinose crosslinking observed here (Fig. 3.5C, D, G, H, 3.7B, C). Chatterjee et al. have reported
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crystallization and phase separation of raffinose during annealing, although the final lyophilized
product was amorphous

41.

In this work, the lyophilized raffinose formulation was amorphous as

observed by X-ray diffraction (data not shown), but raffinose crystallization during freezing or microphase separation in the lyophilized product may have occurred and would not be detected. The
extent to which the hygroscopic nature of raffinose and raffinose-water hydrogen bonding
contributes to decreased peptide-water interactions in the lyophilized raffinose formulation is also
unknown. Moreover, the relative reactivity of the carbene in the solid and solution states and as
well as its rates of reaction with raffinose and water may also contribute, and to date have not been
explored.

While ssPC-MS offers higher resolution structural information than conventional methods such as
FTIR, experimental and computational limitations remain and should be noted. A current
experimental limitation is the inability to resolve the sites of crosslinking at the amino-acid level with
ESI-CID-MS/MS. Higher resolution mass spectrometry instruments (e.g., FTICR-MS) may be
useful for this purpose. Analysis could be simplified by better control of the sites and extent of
protein derivatization. This could be accomplished through optimizing pH, SDA concentration and
reaction time to limit labeling at side-chains that do not contain a primary amine, or by the use of
site-specific derivatization chemistries (e.g., click chemistry). Computationally, though theoretical
mass lists for derivatized and crosslinked peptides can be prepared using software such as
GPMAW, the complete list can be quite long, particularly for larger proteins such as antibodies. In
addition, matching the theoretical list with observed masses using software such as MassHunter
can be time-consuming due to potential false positives that need to be verified manually. Recent
improvements in bioinformatics such as xProphet could allow improved identification of crosslinked
peptides with low false positive rates42. However this technique requires MS/MS information,
preferably from high-resolution LTQ-Orbitrap instruments. More broadly, the effects of water activity
(RH) and excipient type on protein-protein and protein-matrix interactions require further
investigation, as does the relationship of the interactions detected by ssPC-MS to storage stability.
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Nevertheless, the results presented here demonstrate the potential of ssPC-MS for probing proteinprotein and protein-matrix interactions in lyophilized solids with high resolution.

3.6

CONCLUSIONS

ssPC-MS provided qualitative and quantitative measures of protein side-chain interactions in
lyophilized formulations. The environment of lyophilized Mb could be visualized with high resolution
at the peptide-level and excipient differences quantified using X1n* values.

3.7
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CHAPTER 4. STUDYING PROCESS AND FORMULATION EFFECTS ON PROTEIN
STRUCTURE IN LYOPHILIZED SOLIDS USING MASS SPECTROMETRIC METHODS

4.1

ABSTRACT

Myoglobin (Mb) was lyophilized in the absence (Mb-A) and presence (Mb-B) of sucrose in a pilotscale lyophilizer with or without controlled ice nucleation. Cake morphology was characterized
using scanning electron microscopy (SEM) and changes in protein structure were monitored using
solid-state Fourier-transform infrared spectroscopy (ssFTIR), solid-state hydrogen-deuterium
exchange-mass spectrometry (ssHDX-MS) and solid-state photolytic labeling-mass spectrometry
(ssPL-MS). The results showed greater variability in nucleation temperature and irregular cake
structure for formulations lyophilized without controlled nucleation. Controlled nucleation resulted
in nucleation at ~ -5 °C and uniform cake structure. Formulations containing sucrose showed better
retention of protein structure by all measures than formulations without sucrose. Samples
lyophilized with and without controlled nucleation were similar by most measures of protein
structure. However, ssPL-MS showed the greatest pLeu incorporation and more labeled regions
for Mb-B lyophilized with controlled nucleation. The data support the use of ssHDX-MS and ssPLMS to study formulation and process-induced conformational changes in lyophilized proteins.

4.2

INTRODUCTION

Proteins are often marketed in lyophilized form or stored as lyophilized powders after purification
and prior to formulation. Lyophilization begins with freezing, followed by primary drying to remove
bulk ice by sublimation and secondary drying to desorb unfrozen water. Proteins are subjected to
various stresses during lyophilization, including freeze-concentration and denaturation at the icesurface, pH shifts and dehydration-induced aggregation

1-4.

Proteins can be protected from some

of these stresses by modifying the formulation and using stabilizing excipients

5-8.

However, the
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process itself can play a role in determining critical quality attributes (CQAs) of the product. For
example, the cooling rate and type of thermal treatment used may result in entrapment of
metastable intermediates that can crystallize at higher temperatures during manufacturing or
storage

9-11.

Inadequate drying temperature or time can also result in product failure due to

increased moisture content, and processing or storage above the glass transition temperature (Tg)
can result in degradation 12, 13. Cake elegance can be adversely affected by aggressive processing
above the collapse temperature, producing various degrees of macro- and micro-collapse

14, 15.

Higher temperatures during lyophilization can degrade reducing carbohydrate excipients via the
Maillard reaction 16, which may reduce their stabilizing effects.

The freezing step is critical, since parameters such as the degree of supercooling and rate of
freezing can affect the morphology of ice crystals, which in turn affects the rate of primary drying 17,
18.

When a solution is supercooled to a large degree, ice nucleation occurs at lower temperatures

with little time for ice crystal growth, resulting in smaller pores in the dried solid. These small ice
crystals result in small pores and offer greater resistance to flow of water vapor through the porous
bed of partially dried solids. This necessitates the use of a longer primary drying step to remove
crystalline water. In contrast, a lower degree of supercooling is associated with a slower rate of
freezing from a relatively small number of large ice crystals. Since ice nucleation is stochastic,
cycles without controlled freezing are expected to nucleate over a range of temperatures, resulting
in longer freezing times and heterogeneous ice crystal morphology. Variability is also introduced
by vial position within the lyophilizer chamber 19, since vials near the door and walls of the lyophilizer
chamber receive more heat via radiation than those near the center of the chamber. Together,
these factors result in inter-vial- and inter-batch heterogeneity. If left uncontrolled, this variability
may be magnified when a process is scaled from a laboratory bench-top lyophilizer to a production
freeze-dryer. Heat- and mass-transfer differences between pilot and production freeze-dryers may
also play a role, so that the same lyophilization cycle may produce variable product CQAs at
different scales. Controlling the freezing step is critical to producing uniform ice crystal morphology,
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resulting in less variability between samples and faster drying. The freezing rate can also affect
product stability, since smaller ice crystals formed by fast freezing present a greater surface area
for potential protein adsorption and unfolding. Aggregation at the protein solution-ice interface was
implicated in the lyophilization-induced instability of human growth hormone 20, recombinant human
factor XIII 21, lactate dehydrogenase and immunoglobulin G 3.

Strategies to control nucleation include the use of an ice fog as a seeding technique and rapid
depressurization to induce spontaneous nucleation. While the effect of controlled ice nucleation on
primary drying time has been well documented

22-25,

its effect on protein structure is not well

understood. Controlled nucleation at a lower degree of supercooling results in larger ice crystals
with lower surface area for protein adsorption. In addition, since all vials nucleate at the same time
and primary drying time is decreased, the residence time of proteins at the ice surface is reduced.
These two factors are expected to produce a product that is more stable than one lyophilized
without controlled nucleation. The effect of depressurization-induced controlled nucleation on
product characteristics was reported for a monoclonal antibody

26.

Although the drying time was

reduced by ~ 10 h and cake appearance improved to some extent with controlled nucleation, there
was no significant impact on aggregation as detected by UV spectroscopy and size exclusion
chromatography (SEC). Secondary structure was not altered significantly, as quantified by circular
dichroism (CD) spectroscopy. The process did not affect binding to protein-A, suggesting that the
tertiary structure was also intact, at least at the binding site. Other studies investigated the effect of
different lyophilization cycles on protein conformation and cake structure

27, 28.

While cycle

variations typically led to altered cake morphology as detected using scanning electron microscopy
(SEM), conformational changes could not be detected using conventional ssFTIR and solutionstate CD and fluorescence spectroscopy.

In this work, the effects of controlled nucleation and lyophilizer scale on protein structure were
examined. The ControLyo® depressurization technology was used for controlled nucleation.
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Myoglobin (Mb) lyophilized in a LyoStar freeze-dryer with or without controlled nucleation showed
no significant changes in structure at the backbone and side-chain levels, as determined by ssFTIR,
solid-state hydrogen-deuterium exchange (ssHDX-MS) and solid-state photolytic labeling (ssPLMS), respectively. However, formulation effects were dominant and protein structure was better
protected at the backbone in the presence of sucrose. The results indicate that local structure
remains unaltered by controlled nucleation and that ssHDX-MS and ssPL-MS can be used to detect
process- and formulation-induced changes in protein structure.

4.3

MATERIALS AND METHODS
4.3.1

Materials

Equine skeletal muscle holomyoglobin (Mb), sucrose, potassium phosphate dibasic and
ammonium bicarbonate were purchased from Sigma Aldrich (St. Louis, MO). Potassium phosphate
monobasic (anhydrous) was purchased from Amresco (Solon, OH). D2O was obtained from
Cambridge Isotope Laboratories, Inc. (Andover, MA) and photo-leucine (L-2-amino-4, 4′azipentanoic acid) from Thermo Scientific (Rockford, IL). Mass spectrometry-grade water,
acetonitrile and formic acid were purchased from Fisher Scientific (Fair Lawn, NJ). Spectra/Por
dialysis tubing (MWCO 8000-10000 Da) was used to dialyze the protein prior to formulation
(Spectrum Laboratories, Inc., Rancho Dominguez, CA). Syringes (Beckton, Dickinson and
Company, Franklin Lakes, NJ) and 0.2 µm Acrodisc® syringe filters (Pall Corporation, Ann Arbor,
MI) were used to filter the dialysate.

4.3.2

Sample Preparation

Mb was dissolved in potassium phosphate buffer (2.5 mM, pH 7.4) and dialyzed overnight against
the same buffer using dialysis tubing. The dialyzed protein was filtered using a syringe filter and its
concentration measured using UV spectroscopy (8453 UV-Vis, Agilent Technologies, Santa Clara,
CA) and the molar extinction coefficient ε555 nm = 12.92 mM-1cm-1 (obtained from Sigma Aldrich
product information sheet for equine skeletal muscle myoglobin, product M0630). This stock
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solution (345 µM) was used for all formulations. A 20 mg/mL stock solution of sucrose was prepared
by dissolving sucrose in potassium phosphate buffer (2.5 mM, pH 7.4) and stored at 4 °C until use.
Similarly, a 30.9 mM stock solution of photo-leucine (pLeu) was prepared using the same buffer
and stored at 4 °C until use.

Two formulations were prepared for lyophilization: a control formulation containing Mb and buffer
(‘Mb-A’) and a formulation containing Mb, sucrose and buffer (‘Mb-B’). Stock solutions of Mb,
sucrose and buffer were mixed such that the final Mb concentration was 70 µM and the ratio of Mb
to sucrose was 1:1 w/w. For photolytic labeling studies, pLeu was added to Mb-A and Mb-B such
that the molar ratio of pLeu to Mb was 100:1. The weight fractions of each component are listed in
Table 1. The formulations were filled in glass tubing vials (USP Type I glass; 2 ml capacity) with 13
mm necks. The fill volume was 500 µL for ssHDX-MS, ssPL-MS, thermogravimetric analysis, X-ray
diffraction and solid-state Fourier-transform infrared spectroscopy samples. A 3 mL fill in 10 mLcapacity glass beakers was used for scanning electron microscopy.

Table 4.1. Weight fractions of components of lyophilized formulations
% w/w
Lyophilized Formulation

a Mb,

Mb a

Sucrose a

Buffer

pLeu a

Mb-A

91.7

N/A

8.3

N/A

Mb-B

42.9

42.9

14.1

N/A

Mb-A + pLeu

46.0

N/A

15.1

38.8

Mb-B + pLeu

31.5

31.5

10.4

26.6

myoglobin; pLeu, photo-leucine (L-2-amino-4,4′-azipentanoic acid)

4.3.3

Lyophilization

Both Mb-A and Mb-B formulations were lyophilized with and without controlled nucleation during
the freezing step. For freezing with controlled nucleation (LyoStar 3 with ControLyo®, SP Industries,
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Inc., Gardiner, NY), the vials were equilibrated at 5 °C for 30 min, followed by pressurization with
argon gas to 28 psig and a decrease in temperature to -5 °C. A ramp rate of 1 °C/min was used
and the vials were equilibrated at -5 °C for 60 min. At the end of this step, the chamber was rapidly
depressurized to 1 psig to induce controlled nucleation and the temperature was further reduced
to -45 °C at a ramp rate of 1 °C/min and held overnight to complete the freezing step. For freezing
without controlled nucleation (LyoStar II, SP Industries), the vials were equilibrated at 5 °C for 60
min (ramp rate 1 °C/min) and then frozen at -45 °C overnight.

To minimize process variability, vials frozen with and without controlled nucleation were dried
simultaneously in the LyoStar 3 lyophilizer. Vials frozen without controlled nucleation in LyoStar II
were quickly transferred to LyoStar 3 and held at -45 °C for an additional 30 min. A vacuum of 70
mTorr was used and the shelf temperature was increased stepwise with a ramp rate of 1 °C/min (35 °C for 600 min, -20 °C for 600 min, -5 °C for 360 min, 10 °C for 360 min). Product temperature
was monitored during freezing and drying using 30 gauge Type T thermocouple sensors.
Thermocouples were placed either inside the solution or taped to the outside of the vial. Chamber
pressure was monitored using a capacitance manometer (CM) and Pirani gauge. The end point of
each drying step was determined using a pre-set CM/Pirani gauge differential, wherein the cycle
advanced to the next step if the differential was reached at the end of the previous step. Since the
presence of thermocouples inside the solution may affect sample integrity, thermocouplecontaining vials were not used for characterization studies.

4.3.4

X-ray Powder Diffraction

Samples were analyzed by X-ray powder diffraction to detect any crystallinity after lyophilization.
Diffractograms were collected on a 2θ θ scan from 7-35° 2θ with 0.02° increments using a
SmartLab diffractometer (Rigaku Americas, TX).
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4.3.5

Scanning Electron Microscopy (SEM)

Intact lyophilized cakes were removed from beakers and mounted on a sample holder with doublesided tape. The cakes were carefully sliced using a blade and sputter-coated with carbon graphite.
Images were obtained using a JCM-6000 NeoScope benchtop instrument (JEOL USA, Peabody,
MA) in the high vacuum, 15 kV mode.

4.3.6

Solid-State Fourier Transform Infrared (ssFTIR) Spectroscopy

FTIR spectra were acquired for all lyophilized samples using a Tensor 37 spectrometer (Bruker
Optics, Billerica, MA), as described previously 29. 128 scans were obtained at 4 cm-1 resolution and
spectra were processed using OPUS software (v. 6.5, Bruker Optics), by cutting around 1600-1700
cm-1, smoothing and baseline correcting before obtaining second derivative spectra.

4.3.7

Thermogravimetric Analysis (TGA)

Moisture sorption kinetics was measured using TGA (QA5000SA, TA Instruments, New Castle, DE)
to study its effect on hydrogen-deuterium exchange kinetics. ~ 1 mg of lyophilized protein (with or
without sucrose) was loaded onto a metallized quartz sample pan. The loosely bound water was
removed by heating the sample to 40 °C, 0 % RH inside the sample chamber until the weight
change was < 0.01 % and equilibrated for 1 h. The sample was then equilibrated at 5 °C, 0 % RH
for 1 h, followed by moisture sorption at 5 °C, 43 % RH for 3 h inside the sample chamber. Initial
moisture content was calculated from the weight change before and after equilibration at 40 °C, 0 %
RH for 1 h.

4.3.8

Solid-state Hydrogen Deuterium Exchange- Mass Spectrometry (ssHDX-MS)

Lyophilized vials were uncapped and placed in a sealed desiccator equilibrated at 43 % RH over
D2O (obtained with a saturated solution of potassium carbonate in D2O). HDX was allowed to
proceed at 5 °C for 0.5, 2, 6, 12, 24, 48, 84 and 120 h. At each time point, samples were withdrawn,
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stoppered and flash-frozen in liquid N2 to quench the exchange reaction. The samples were stored
at -80 °C until analysis.

HPLC-MS (1200 series HPLC, ESI-qTOF 6520, Agilent Technologies, Santa Clara, CA) was used
to measure deuterium uptake at the intact level, as described previously 29, 30. Deuterated samples
were reconstituted with 2 mL of ice-cold quench buffer (5 % methanol, 0.2 % formic acid in LC-MSgrade water, pH 2.5) and injected into a refrigerated box housing the HPLC valves, tubing and
protein microtrap at ~ 0 °C to reduce back-exchange. The protein was eluted with a gradient mobile
phase that increased from 30 % to 80 % acetonitrile over 3 min. Mass spectra for deuterated
samples were deconvoluted using MassHunter software (Agilent Technologies), and the number
of deuterons incorporated was calculated by subtracting the mass of the undeuterated protein from
the mass of the deuterated protein. Peak widths of the deconvoluted intact protein spectra were
measured at 20 % peak height.

4.3.9

Solid-state Photolytic Labeling- Mass Spectrometry (ssPL-MS)

Lyophilized Mb-A and Mb-B vials containing pLeu were uncapped and irradiated at 365 nm for 40
min using Stratalinker 2400 (Stratagene Corp., La Jolla, CA) as described previously 31. The cakes
were then reconstituted with 500 µL ammonium bicarbonate (100 mM, pH 8.0), diluted to 20 pmol
and analyzed at the intact protein level by LC-MS. The same elution parameters were used as
described above for ssHDX-MS, but with analysis performed at room temperature since the pLeu
label does not undergo back-exchange. The fractions of protein populations with 0-2 labels (F
1, 2)

L=0,

were calculated from peak heights observed on the extracted ion chromatogram (EIC), as

follows:

𝐹𝐹𝐿𝐿=0,1,2 =

(Peak height)𝐿𝐿=0,1,2
(Peak height)𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐿𝐿=0 + (Peak height)𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝐿𝐿=1,2
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To identify the sites of labeling at the peptide level, the labeled Mb formulations were digested with
trypsin (1:10 ratio of trypsin to protein) at 60 °C for 16 h. Labeled peptides were analyzed by LCMS using the method described previously

31

and identified with MassHunter, using a theoretical

mass list of tryptic peptides with up to 2 labels.

4.3.10 Statistical Analysis
Process- and excipient effects on protein structure were compared statistically using GraphPad
Prism software (GraphPad software, version 6; La Jolla, CA). One-way ANOVA followed by Tukey’s
test was used for multiple comparisons (p = 0.05).

4.4

RESULTS

In the absence of solution and vial impurities, a solution can remain in a supercooled liquid state
without undergoing phase transition into a solid as the temperature is lowered below its freezing
point. When water crystallizes into ice, an increase in product temperature is detected associated
with the latent heat of fusion. Product temperature bias due to the presence of the thermocouple in
solution must be considered, since it can increase the nucleation temperature

32.

To avoid

thermocouple-related artifacts in temperature, some thermocouples were taped to the outside of
the vial. Vials with thermocouples also tend to dry faster, since ice nucleation at higher
temperatures produces larger ice crystals with lower resistance during drying 33. Although vials with
thermocouples may not measure true product temperature, a comparison of product temperatures
between processes can still be made using thermocouple-containing vials.

4.4.1

Effect of Freezing Step on Nucleation Temperature

Product temperatures for Mb-A (excipient-free formulation) and Mb-B (sucrose-containing
formulation) frozen with and without controlled nucleation were recorded (Fig. 4.1 A, B). In the
absence of controlled nucleation, variable nucleation temperatures were recorded ranging from 5.7 °C to -9.4 °C (mean ± SD, Fig. 4.1A) and all the thermocouple-containing vials nucleated within
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10 min. With controlled nucleation, all the vials containing thermocouples inside the solution
nucleated simultaneously at -5.3 ± 0.2 °C (Fig. 4.1B), irrespective of formulation. Vials with
thermocouples taped to the outside reported nucleation temperatures of -4.0 °C (Mb-A) and -4.4 °C
(Mb-B) with controlled nucleation.

Figure 4.1. Product temperature profiles for excipient-free (Mb-A) and sucrose-containing (Mb-B)
myoglobin lyophilized without controlled nucleation (panel A) and with controlled nucleation (panel
B). Thermocouple probes (TC) were placed inside the vial (labeled Mb-A in, Mb-B in) or taped to
the outside of the vial (labeled Mb-A out, Mb-B out). The shelf set point (shelf SP) temperature is
represented by the black line in panels A and B.

4.4.2

Measurement of Supercooling during the Freezing Step

To estimate the extent of supercooling in freezing with uncontrolled nucleation, thermocouples were
taped to the outside of the vial to avoid thermocouple-related bias. However, this may introduce
uncertainty as a thermal lag is expected for thermocouples placed on the outside of the vial. Hence
thermocouples were placed both outside and inside the vial for 2 vials each for Mb-A and Mb-B.
These thermocouples reported similar temperatures, suggesting that thermal lag was minimum and
the nucleation temperature recorded was reproducible (Fig. 4.2 A, B). Mb-A showed supercooling
to ~ -7.5 ± 0.4 °C and Mb-B showed supercooling to ~ -9.1 ± 0.4 °C, as measured by thermocouples
placed both inside and outside the vial. Moreover, vials with thermocouples only in contact with the
solution showed greater supercooling than vials with thermocouples only on the outside (Fig. 4.1A).
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The reason for this is unclear and the data are contrary to the expected result of increased
nucleation temperature due to the presence of the thermocouple.

Figure 4.2. Extent of supercooling for excipient-free (Mb-A, panel A) and sucrose-containing (MbB, panel B) myoglobin formulations lyophilized without controlled nucleation. Thermocouples were
placed inside the vial in contact with the solution and also taped to the outside of the same vial.
Mb-A showed supercooling to ~ -7.5 ± 0.4 °C and Mb-B showed supercooling to ~ -9.1 ± 0.4 °C as
measured by thermocouples placed both inside and outside the vial.

4.4.3

Solid-State Characterization by X-ray Diffraction and FTIR

All the formulations were amorphous after freeze-drying and produced X-ray diffraction patterns
consistent with amorphous materials (Appendix Fig. A9). Both Mb-A and Mb-B retained some
degree of alpha helicity, observed as a peak at about 1652 cm-1 in the second-derivative FTIR
spectra (Fig. 4.3). Mb-B with and without controlled nucleation showed a more intense and
narrower alpha helix peak than excipient-free Mb-A formulations, although there was no
appearance of beta sheet peaks in any of the spectra (Fig. 4.3). Overall, the two processes appear
to have affected peak intensity and position, but without the formation of non-native secondary
structure.
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Figure 4.3. Second-derivative solid-state FTIR spectra for excipient-free (Mb-A) and sucrosecontaining (Mb-B) lyophilized myoglobin formulations. Spectra were obtained for Mb-A and Mb-B
lyophilized with controlled nucleation (black and red curves respectively) and without controlled
nucleation (blue and green curves respectively).

4.4.4

Cake Morphology

SEM images showed porous cakes for all formulations. Mb-A and Mb-B lyophilized with controlled
nucleation showed more uniform pore structure than the formulations lyophilized without controlled
nucleation (Fig. 4.4, Appendix Fig. A10). Mb-A lyophilized with and without controlled nucleation
showed large plate-like morphology (Appendix Fig. A10, panels A, B) and Mb-B lyophilized with
and without controlled nucleation showed thinner plates (Appendix Fig. A10, panels C, D). The data
are consistent with the degree of supercooling (Fig. 4.1), since the formulations lyophilized with
controlled nucleation showed a lower degree of supercooling and larger pores than those
lyophilized without controlled nucleation.
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Controlled Nucleation

A

B

C

D

Uncontrolled
Nucleation

Mb-A

Mb-B

Figure 4.4. SEM images of excipient-free (Mb-A; panels A, B) and sucrose-containing (Mb-B;
panels C, D) lyophilized myoglobin formulations. Panels A, C: Formulations lyophilized with
controlled nucleation; Panels B, D: Formulations lyophilized without controlled nucleation. The top
and bottom of each image represent the top and bottom of the cake respectively. Scale bars are
set at 1 mm.

4.4.5

Effects of Formulation and Process on Protein Backbone by ssHDX-MS

Deuterated intact protein mass spectra showed an increase in mass compared to the undeuterated
protein (Fig. 4.5). Since sorption and diffusion of D2O from the vapor phase into the solid must
precede the hydrogen-deuterium exchange reaction in the solid state, the observed ssHDX rate
can be affected by the rate and extent of sorption

30.

To determine the effect of D2O sorption on

ssHDX kinetics, moisture uptake was measured using TGA to simulate D2O uptake at 43 %
humidity. Moisture sorption at 43 % RH was complete within 1 h for both Mb-A and Mb-B
formulations, irrespective of the type of freezing (Appendix, Fig. A11). Since ssHDX continues over
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several hours, it is unlikely that sorption kinetics have a significant effect on ssHDX kinetics beyond
1 h.

Figure 4.5. Deconvoluted mass spectra for excipient-free (Mb-A) and sucrose-containing (Mb-B)
myoglobin formulations after 48 h of solid-state hydrogen-deuterium exchange at 5 °C, 43 % RH.
Mass spectra were obtained for Mb-A and Mb-B lyophilized with controlled nucleation (blue and
green curves respectively) and without controlled nucleation (red and orange curves respectively).
The dashed curve represents the deconvoluted spectrum for undeuterated protein.

ssHDX was relatively rapid in both Mb-A and Mb-B formulations lyophilized with or without
controlled nucleation up to ~ 24 h and slowed at ~ 84 h for all samples (Fig. 4.6 A, B). At each time
point, sucrose-containing formulations showed significantly lower deuterium uptake than the
excipient-free formulations, suggesting greater backbone protection in the solid state. Deuterium
uptake in the Mb-A formulation was not significantly different (p > 0.05) when the protein was frozen
with or without controlled nucleation (Fig. 4.6A); similar results were observed for Mb-B with or
without controlled nucleation (Fig. 4.6B). The initial moisture content after lyophilization (without
incubation over water or D2O) of the formulations as measured by TGA were as follows: 2.9 % (MbA, controlled nucleation), 4.0 % (Mb-A, uncontrolled nucleation), 3.4 % (Mb-B, controlled nucleation)
and 3.1 % (Mb-B, uncontrolled nucleation). Using TGA to simulate D2O sorption and measure
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moisture sorption at 43 % RH, differences in moisture sorption were observed between Mb-A and
Mb-B formulations, but not between controlled and uncontrolled nucleation. Mb-A lyophilized with
and without controlled nucleation sorbed ~ 0.12 and 0.13 g water/g dry solid respectively (~ 12.3 %
and 12.7 % moisture respectively), and Mb-B lyophilized with and without controlled nucleation
sorbed ~ 0.09 g water/g dry solid respectively (~ 9.4 % moisture for both; Appendix Fig. A11) within
1 h of incubation. Hence the increased deuterium uptake for Mb-A may be related to the extent of
moisture sorption, at least until 1 h.

Figure 4.6. (A) Deuterium uptake kinetics for excipient-free myoglobin (Mb-A) lyophilized with
controlled nucleation (closed circles) and without controlled nucleation (open circles). (B)
Deuterium uptake kinetics for myoglobin-sucrose formulation (Mb-B) lyophilized with controlled
nucleation (closed triangles) and without controlled nucleation (open triangles). (C) Deuterium
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uptake kinetics for Mb-A (circles) and Mb-B (triangles) lyophilized with controlled nucleation. (D)
Deuterium uptake kinetics for Mb-A (circles) and Mb-B (triangles) lyophilized without controlled
nucleation. Each point represents the average number of deuterons (± SD) incorporated after
incubation at 43 % RH, 5 °C for 0.5, 2, 6, 12, 24, 48, 84 and 120 h.

Comparison of peak widths at similar deuterium uptake levels can provide information on the
conformational and/or spatial heterogeneity of protein in different formulations. The sucrose
formulation lyophilized with or without controlled nucleation showed significantly narrower peak
widths (p < 0.05) than the excipient-free formulation at ~ 28 % deuteration (Fig. 4.5, Table 4.2).
Peak widths for Mb-B were about 26 % smaller than those for Mb-A formulations, irrespective of
the type of freezing. No significant differences in peak widths were observed between controlled
and uncontrolled nucleation within each formulation.

Table 4.2. ssHDX-MS peak widths for myoglobin formulations in the absence (Mb-A) and presence
(Mb-B) of sucrose lyophilized with or without controlled nucleation. Peak widths at ~28 %
deuteration were calculated from the deconvoluted mass spectra for each formulation at 20 % peak
height.
Peak Width (Da)
Formulation

a

Controlled Nucleation

Uncontrolled Nucleation

Mb-A a

38.0 ± 1.0

38.3 ± 0.6

Mb-B a

28.0 ± 0.0

27.7 ± 0.6

Mb-A, myoglobin lyophilized without excipients; Mb-B, myoglobin lyophilized with sucrose

4.4.6

Effects of Formulation and Process on Protein Side-Chain by ssPL-MS

Up to 2 pLeu labels were detected for all formulations lyophilized with pLeu and irradiated with UV
light (Fig. 4.7A). Mb-A lyophilized with and without controlled nucleation showed similar pLeu
incorporation (Fig. 4.7B). About 7 (± 1) % and 6 (± 1) % of the protein population was labeled for
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Mb-A with and without controlled nucleation respectively, as detected by LC-MS. Similar pLeu
incorporation (7 ± 1 %) was observed for Mb-B without controlled nucleation. The greatest pLeu
incorporation was detected for Mb-B with controlled nucleation (11 ± 1 %). Comparing Mb-A and
Mb-B formulations lyophilized with controlled nucleation, the fraction of intact protein labeled
increased significantly for Mb-B. There was no significant difference in the fraction of labeled protein
in Mb-A and Mb-B formulations lyophilized without controlled nucleation.

Figure 4.7. (A) Deconvoluted mass spectra for unlabeled myoglobin (dotted line) and myoglobin
labeled with photo-leucine (solid line). The spectrum for labeled myoglobin has been offset
vertically to show differences. Peaks corresponding to the mass of unlabeled (0 L, ~ 16951 Da)
and protein with 1 label (1 L, ~ 17066 Da) were detected. A peak for myoglobin labeled with 2 labels
(~ 17182 Da) was also detected, but not shown here since the intensity was low. Similar spectra
with up to 2 labels were obtained for excipient-free (Mb-A) and sucrose-containing (Mb-B)
myoglobin formulations lyophilized with and without controlled nucleation. (B) Fraction of protein
labeled with photo-leucine for Mb-A and Mb-B formulations lyophilized with controlled nucleation
(CN) or without controlled nucleation (UCN). The fraction was calculated using peak heights of
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labeled protein on the extracted ion chromatogram (EIC) obtained by LC-MS. The bars show the
mean (± SD) of three LC-MS injections. The following pairs showed significantly different means (p
< 0.05, GraphPad Prism) using one-way ANOVA: Mb-A CN vs. Mb-B CN and Mb-B CN vs. Mb-B
UCN.

At the peptide level, complete sequence coverage was obtained after tryptic digestion and LC-MS
analysis. Since photolytic labeling is associated with some degree of variability due to promiscuity
of the carbene reaction, matrix heterogeneity and ionization efficiencies of labeled and unlabeled
peptides, only labeled peptides that were detected in at least 2 of triplicate LC-MS injections were
considered. Mb-A lyophilized with controlled nucleation and Mb-A and Mb-B lyophilized without
controlled nucleation were labeled at peptide His103-Lys118 (Fig. 4.8A). Mb-B lyophilized with
controlled nucleation was labeled at peptides Leu32-Lys42 and His103-Lys118 (Fig. 4.8B).

A

B

Leu32-Lys42

Tyr103-Lys118
Figure 4.8. Peptide-level labeling with photo-leucine for (A) excipient-free (Mb-A) myoglobin
lyophilized with controlled nucleation. (B) Sucrose-containing (Mb-B) myoglobin lyophilized with
controlled nucleation. Labeled peptides Leu32-Lys42 and Tyr103-Lys118 are represented in blue and
the heme group is shown in red. Mb-A and Mb-B lyophilized without controlled nucleation showed
the same labeling pattern on Tyr103-Lys118 as represented in panel (A). The crystal structure for
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holomyoglobin was obtained from the Protein Data Bank (www.rcsb.org; PDB ID 1WLA) and
PyMOL was used to generate labeled ribbon diagrams (PyMOL Molecular Graphics System,
Version 1.4.1, Schrödinger, LLC).

4.5

DISCUSSION

During scale-up in an aseptic environment, vials are expected to supercool to a greater degree
than in a laboratory environment where there are more particulates. This, combined with vial
position effects and the stochastic nature of ice nucleation, produces heterogeneous nucleation
temperatures and ice crystal sizes in the sterile environment, resulting in prolonged drying cycles.
Controlled nucleation can help improve inter-vial and inter-batch homogeneity and reduce drying
times. Lyophilization-induced structural changes may affect protein stability when a process is
transferred from laboratory-scale to production, however, and these changes may not be detected
using conventional, global methods such as ssFTIR and differential scanning calorimetry. Here, we
report the use of high-resolution ssHDX-MS and ssPL-MS to detect conformational changes in
lyophilized formulations with process and formulation differences.

ssHDX-MS results indicate that deuterium incorporation was affected significantly by formulation,
but not the freezing step (Figs. 4.5, 4.6). Deuterium incorporation in the excipient-free formulation
(Mb-A) was greater than in the formulation containing sucrose (Mb-B), consistent with greater
structural perturbation and/or a decrease in matrix interactions in Mb-A (Fig. 4.5). Deuterium
incorporation in both the excipient-free formulation and the sucrose-containing formulation was
relatively unaffected by the freezing step (Fig. 4.5, orange vs. green curves, blue vs. red curves).
That the type of freezing (controlled vs. uncontrolled nucleation) does not affect deuterium
incorporation for both Mb-A and Mb-B suggests that the process does not significantly alter protein
structure in this study. These findings are supported by ssHDX-MS kinetics (Fig. 4.6) and are
consistent with trends in FTIR band position and band intensity (Fig. 4.3).
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In analyzing deuterium uptake kinetics, the peak width provides a measure of protein structural
heterogeneity resulting from the distribution of deuterated populations

34, 35.

Small increases in

mass due to deuteration may not be detected if the peaks are not sufficiently resolved. This can
cause peak broadening, wherein multiple deuterated populations comprise a wider peak. Peak
widths for the Mb-A formulation were significantly greater than for Mb-B for both processes,
consistent with greater structural and/or spatial heterogeneity in Mb-A than in Mb-B (Table 4.2).
Within Mb-A or Mb-B formulations, peak widths for samples from the two processes were not
significantly different (Table 4.2), suggesting similar structural and/or spatial heterogeneity with
controlled and uncontrolled nucleation.

Like ssHDX-MS, ssPL-MS provides qualitative and quantitative information on proteins in the solid
state. Since the mass of a pLeu label (~ 115 Da) is much greater than that of a deuterium label,
mass spectrometric peaks for unlabeled and singly labeled protein can be resolved easily and peak
broadening is not observed. Assuming uniform pLeu distribution in the matrix, the fraction of protein
labeled by pLeu quantifies the fraction of protein with side-chain exposure to pLeu. The fraction of
labeled protein and map of the labeled regions (Figs. 4.7B, 4.8) provide information on pLeu
exposure at the side-chain level. In the presence of sucrose in the lyophilized matrix, it is expected
that pLeu labeling efficiency will be somewhat diluted, resulting in decreased labeling compared to
an excipient-free formulation. However, pLeu labeling was similar (uncontrolled nucleation) or
greater (controlled nucleation) in the Mb-B formulation compared to Mb-A (Fig. 4.7). Within Mb-A
formulations, the fraction of labeled protein was similar (Fig. 4.7) and within Mb-B formulations, the
fraction of labeled protein was greater for controlled nucleation than for uncontrolled nucleation,
consistent with greater interactions with the matrix. This suggests that while uncontrolled nucleation
results in equivalent side-chain matrix exposure in the presence or absence of sucrose, controlled
nucleation affects side-chain exposure in the presence of sucrose.
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Intact- and peptide-level pLeu labeling data indicate that side-chain exposure to pLeu is different
for Mb-B lyophilized with controlled nucleation than for the other formulations, suggesting more
favorable contacts between the protein and pLeu (Figs. 4.7, 4.8). The reasons for the increased
fraction of labeled protein in Mb-B with controlled nucleation are not clear, but may be related to
the distribution of pLeu and protein in the formulation and/or changes in protein conformation.
Inhomogeneity in the freeze-concentrated liquid after ice crystallization has been reported
previously

36-38.

Efficiency of UV light penetration may also affect protein labeling. Smaller fill

volumes result in lower cake height and better labeling efficiency (Appendix Fig. A12). Hence,
ssPL-MS may not be representative of protein structure across the entire cake. Moreover, the
uniform and large pore structure for Mb-B lyophilized with controlled nucleation may permit more
efficient irradiation and pLeu labeling. Labeling of sucrose by pLeu was not detected by LC-MS,
but may also affect protein labeling. Previous ssPL-MS results in our lab showed greater protein
labeling in the presence of sucrose compared to guanidine hydrochloride

31.

It is difficult to

distinguish the effect of excipients from the effect of protein conformation on the nature of solidstate labeling observed, and stability studies are needed to correlate the fraction of labeled protein
with structure retention and interpret the side-chain labeling results.

Together, the results show that controlled nucleation did not significantly affect protein conformation
in this study as determined by ssFTIR and ssHDX-MS (Figs. 4.5, 4.6, 4.7 and 4.8) and may offer
the advantage of reduced drying time. A similar absence of structural changes has been reported
for IgG lyophilized with and without controlled nucleation

26,

although solution-state analytical

methods were used. In this study, formulation effects were more dominant than process effects.
Additional studies on the effects of controlled nucleation on protein structure are needed in order
to extend these results to other proteins, using a variety of protein-excipient systems.

There were several unexpected observations in this study that merit further investigation. In
preliminary controlled nucleation experiments using a fill volume of 200 µL and nitrogen as the gas
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for pressurization, nucleation did not take place at -5 °C. Instead, nucleation proceeded in an
uncontrolled manner. Controlled nucleation at -5 °C did take place when a fill volume of 500 µL
was used in combination with argon as the pressurization gas. Further investigation is needed in
order to understand the role of vial size, relative fill volume, and pressurization gas on the
robustness of the nucleation process using rapid depressurization. Controlled nucleation by rapid
depressurization is highly directional, always proceeding from the top of the fill volume downward.
For very small fill volumes, the dynamics of this top-down process is quickly interrupted. It would
be useful to study the effect of relative fill volume on protein structure perturbation using controlled
nucleation by rapid depressurization. Generally speaking, the vials containing thermocouples
nucleate before the unmonitored vials.

That did not happen when monitoring uncontrolled

nucleation in this study. In fact, the vials containing thermocouples nucleated last. This could have
been a random occurrence, but it may be useful to further examine the influence of thermocouples
on nucleation when using very small fill volumes.

Previous ssHDX-MS studies in our lab have shown a correlation between deuterium incorporation
in freshly lyophilized samples and aggregation during storage over a year, with greater stability for
formulations showing lower deuterium incorporation

29.

It is reasonable to expect a similar

correlation for process-induced differences in ssHDX, though extended storage stability studies
were not conducted here. Based on this previous report and the ssHDX-MS results for intact Mb
presented here (Fig. 4.5), stability would be expected to decrease in the order: (Mb-B without
controlled nucleation) = (Mb-B with controlled nucleation) > (Mb-A without controlled nucleation) =
(Mb-A with controlled nucleation). A similar trend in structure retention was observed by ssFTIR,
although the data are qualitative. To our knowledge, the relationship between ssPL-MS results and
storage stability has not yet been explored.
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4.6

CONCLUSIONS

Two formulations of Mb (with or without sucrose) were lyophilized according to the same
lyophilization cycle with or without controlled nucleation and the effects on Mb conformation in the
lyophilized solids were assessed using ssFTIR, ssHDX-MS and ssPL-MS. Formulation effects were
dominant, with formulations containing sucrose showing better retention of structure by all
measures than formulations without sucrose. Samples lyophilized with controlled nucleation did not
differ from those lyophilized without controlled nucleation by most measures of structure. ssPL-MS
showed greater pLeu incorporation and the involvement of more regions of the Mb molecule in Mb
lyophilized with controlled nucleation in the presence of sucrose than for other conditions. The data
support the use of ssHDX-MS and ssPL-MS to study formulation and process-induced
conformational changes in lyophilized proteins.
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CHAPTER 5.

CONCLUSIONS

This dissertation has described novel, high-resolution techniques to probe protein structure and
environment in the solid state. These techniques are orthogonal to conventional analytical methods
such as FTIR and Raman spectroscopy and provide peptide- to amino acid-level information about
changes in protein structure and microenvironment in the solid state.

The research presented in Chapter 2 shows the potential of solid-state photolytic labeling- mass
spectrometry (ssPL-MS) to study protein structure with high resolution. Although labeling
approaches have been described in solution, these have not been applied to the solid state
previously, to the authors’ knowledge. Solid-state labeling overcomes the low resolution of methods
such as Fourier-transform infrared (FTIR) spectroscopy and allows direct visualization of side-chain
matrix accessibility. It does not depend on pH and can label the entire protein surface.

ssPL-MS can be used to study storage stability in lyophilized formulations by measuring the change
in side-chain accessibility. For example, vials containing lyophilized protein formulation with pLeu
in the matrix can be stored at high temperature and/or humidity for accelerated stability studies.
Samples can be withdrawn at definite intervals, irradiated and analyzed by LC-MS at the intact
protein- and peptide level. Side-chain accessibility of peptides can be quantified using relative peak
heights of unlabeled and labeled peptides obtained by LC-MS. This metric can be correlated with %
monomeric protein observed by size exclusion chromatography. ssPL-MS can also be used to
study the mechanism of solid-state aggregation by labeling protein formulations over the time
course of aggregation and studying changes in side-chain matrix accessibility.
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The crosslinking approach described in Chapter 3 advances the labeling technique by allowing the
protein structure as well as environment to be probed. Thus far, the effect of excipients on
lyophilized protein structure has only been probed indirectly, based on FTIR band areas

1, 2.

However, it is not clearly understood how the mechanism of protein stabilization changes when a
protein in solution is lyophilized. To the authors’ knowledge, this is the first report of direct
visualization of protein-matrix interactions in the solid state. The microenvironment around the
protein could be examined with 3.9 Å resolution, comparable to X-ray crystallography resolution
but without the need for large amounts of protein, isotopic labeling or crystallinity requirements.

The effects of the excipients’ physical form on protein local structure were also observed using
photolytic crosslinking. It is generally accepted that a stabilizing excipient must be in an amorphous
state with the protein to allow better mixing and physical contact. Hence, excipients that remain
amorphous during lyophilization, such as sucrose and trehalose, are expected to stabilize the
protein to a greater degree than crystallizing excipients such as sodium chloride and mannitol. As
described in Chapter 2, the microenvironment around the protein changed significantly when it was
lyophilized, as observed by changes in the crosslinked adducts observed by LC-MS. Although
guanidine hydrochloride (Gdn HCl) was in intimate contact with the protein in solution and caused
protein unfolding, the excipient appeared to crystallize during lyophilization and produced different
crosslinking patterns compared to solution. The raffinose formulation was expected to be more
stable since carbohydrates such as sucrose and trehalose tend to remain in an amorphous phase
with the protein during lyophilization 3. Although crystallinity was not detected by X-ray diffraction,
the crosslinking patterns indicated possible micro-phase separation in the solid state. Such phase
separating, albeit non-crystallizing, excipients may not provide adequate stabilization during
lyophilization and/or storage.

This research can be applied to other amorphous protein systems spanning a range of secondary
structure content, with commonly used disaccharide excipients such as sucrose and trehalose.
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Concentrations of disaccharides in the formulations can also be varied to study their effect on
crosslinking patterns. Crosslinking data obtained from different protein and excipient systems can
help build a model to describe and predict protein stability in the solid state. Furthermore, this
method has the potential to provide insight into the mechanisms of protein stabilization by
excipients, both in solution and solid state. Thus protein crosslinking can aid rational design of
formulations.

The Food and Drug Administration’s (FDA) emphasis on Quality by Design recognizes the need to
improve product quality and reduce the risk of failure. This requires better analytical and predictive
tools to identify process- and product-related variables and ultimately control them, thereby creating
a Design Space. The results described in Chapter 4 showed that controlled ice nucleation did not
affect local protein conformation significantly and that process- and excipient-related effects on
protein local structure in the solid state can be monitored using high-resolution solid-state
hydrogen-deuterium exchange-mass spectrometry (ssHDX) and solid-state photolytic labelingmass spectrometry (ssPL-MS). The results highlight the potential of these analytical methods as
QbD tools to provide predictive measures of protein stability.

Gaps still exist in our knowledge of process effects on protein structure and function. While it is of
interest to make the lyophilization process more efficient, the consequences of process-related
stresses on protein stability must be evaluated during manufacture as well as storage. Proteins that
are sensitive to lyophilization-induced structural changes such as lactate dehydrogenase and
human growth hormone can be used as model proteins. ssHDX-MS, ssPL-MS and ssPC-MS can
be used to study protein conformation changes as a function of lyophilization cycle parameters
such as freezing and drying temperatures and times and chamber pressure. The effect of protein
concentration, fill volume, type of excipient, vial shape and material must also be investigated.
Storage stability studies at different temperatures and relative humidity can be performed with
ssHDX and photolytic methods. The use of high-resolution metrics such as the number of
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exchangeable amides, number of pLeu labels and number of protein-matrix adducts to describe
product stability (using % monomer determined by size exclusion chromatography) must be
evaluated. Thus, high-resolution methods for backbone and side-chain conformational change in
the solid state have potential as tools for rational formulation design, storage stability and product
quality evaluation.
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Figure A1. Digest map of native apoMb digested with a combination of trypsin and chymotrypsin.
A total of 36 peptides were produced, of which the 13 shown by the shaded bars were selected to
provide 100% sequence coverage.
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Table A1. Theoretical and observed b- and y-ions from MS/MS analysis of native and labeled L32K42 in apoMb labeled with pLeu in lyophilized solids.

I. Product ions with z=+1 produced by fragmenting native L32-K42 (m/z = 424.5609; z=+3)
b-ions

Theoretical

Observed

m/za

m/zb

L

b1

114.0919

F

b2

261.1604

T

b3

G

y-ions

Theoretical

Observed

m/za

m/zb

y11

1271.6636

261.1586

y10

1158.5796

362.2080

362.2050

y9

1011.5111

1011.5070

b4

419.2295

419.2223

y8

910.4635

910.4603

H

b5

556.2884

556.2834

y7

853.442

853.4381

P

b6

653.3412

y6

716.3831

716.3800

E

b7

782.3838

782.3758

y5

619.3303

619.3267

T

b8

883.4314

883.4253

y4

490.2877

490.2852

L

b9

996.5155

y3

389.2401

389.2385

E

b10

1125.5581

y2

276.1560

276.1544

K

b11

1253.6531

y1

147.1134

147.1119
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II. Product ions with z=+2 produced by fragmenting native L32-K42 (m/z = 424.5609; z=+3)
y-ionsc

Theoretical

Observed

m/za

m/zb

L

y11

636.3357

636.3344

F

y10

579.7937

579.7910

T

y9

506.2595

506.2572

G

y8

455.7357

455.7332

H

y7

427.2249

427.2230

P

y6

358.6955

358.6935

E

y5

310.1691

T

y4

245.6478

L

y3

195.1240

E

y2

138.5819

K

y1

74.0606
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III. Product ions with z=+2 produced by fragmenting labeled L32-K42 (m/z = 462.9133; z=+3)
y-ions

(A)

(B)

(C)

Mass difference (u)d

Theoretical

Observed

Observed

M = Mlabeled – Munlabeled

m/z

m/z

m/z

(labeled)

(labeled)

(unlabeled)

L

y11

693.8674

693.8649

F

y10

637.3254

637.3184

579.789

115.0588

T

y9

563.7912

563.7873

506.2524

115.0698

G

y8

513.2673

513.2592

455.7365

115.0454

H

y7

484.7566

484.7525

427.2245

115.0560

P

y6

416.2271

416.2189

358.6996

115.0386

E

y5

367.7008

T

y4

303.1795

L

y3

252.6556

E

y2

196.1136

K

y1

131.5923
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IV. Product ions with z=+1 produced by fragmenting labeled L32-K42 (m/z = 462.9133; z=+3)

y-ionsc

(A)

(B)

(C)

Mass difference

Theoretical

Observed

Observed

M = Mlabeled –

m/z

m/z

m/z

Munlabeled

(labeled)

(labeled)

(unlabeled)

L

y11

1386.7269

F

y10

1273.6429

T

y9

1126.5744

G

y8

1025.5268

H

y7

968.5053

P

y6

831.4464

831.4462

716.3819

115.0643

E

y5

734.3936

734.3989

619.3205

115.0784

T

y4

605.3510

605.3535

490.289

115.0645

L

y3

504.3034

389.2466

E

y2

391.2193

276.1541

K

y1

262.1767

147.1118

a

Calculated m/z values.

b

m/z values obtained experimentally using mass spectrometry.

c No
d

b-ions were detected by MS for z = +2.

Mass difference M was calculated from m/z values in columns (B) and (C), using the formula M

=(m/z)*n – nH, where n is the number of charges on the y-ion and H is the mass of a proton (H=1.01
u).
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Table A2. Theoretical and observed b- and y-ions from MS/MS analysis of GCG (1-8)* dimer
from formulation containing peptide lyophilized with L-leu. F* denotes p-benzoyl-Lphenylalanine (pBpA). Calculated m/z values are denoted as ‘Theoretical m/z’ while m/z values
obtained experimentally using mass spectrometry are denoted as ‘Observed m/z’.

I. Internal fragment (non-cross-linked) product ions with z=+1 produced by fragmenting GCG (18)* dimer (m/z = 646.2783; z=+3)
b-

Theoretical

Observed

ions

m/zb

m/zc

H

b1

138.0668

138.0656

y8

968.4110

S

b2

225.0988

225.0973

y7

831.3521

Q

b3

353.1574

353.1502

y6

744.3201

G

b4

410.1789

y5

616.2615

T

b5

511.2265

y4

559.2400

559.2367

F*a

b6

762.3207

y3

458.1923

458.1916

T

b7

863.3684

y2

207.0981

207.0963

S

b8

950.4004

y1

106.0505

106.0497

511.2234

y-ions

Theoretical

Observed

m/zb

m/zc
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II. Cross-linked product ions with z=+2 produced by fragmenting GCG (1-8)* dimer (m/z =
646.2783; z=+3)
b~α-ionsd

Theoretical

Observed

α~y-

Theoretical

Observed

m/zb

m/zc

ions

m/zb

m/zc
968.9178

H

b1

553.2400

y8

968.9173

S

b2

596.7560

y7

890.8773

Q

b3

660.7853

y6

847.3613

847.3526

G

b4

689.2960

689.2939

y5

783.3320

783.3290

T

b5

739.8198

739.8130

y4

754.8213

F*

b6

865.3669

865.3627

y3

704.2975

T

b7

915.8908

915.8929

y2

578.7504

S

b8

959.4068

y1

528.2265

a

F* = p-benzoyl-L-phenylalanine (pBpA).

b

Calculated m/z values.

c

m/z values obtained experimentally using mass spectrometry.

dα

= GCG (1-8)* monomer.

Table A3. List of SDA-labeled tryptic peptides selected for LC-MS/MS analysis.
(Gly1-Lys16) L1 a

(His48-Lys56) L1

(Leu32-Lys45) L1

(Lys79-Lys96) L1

(Leu32-Lys47) L1

(His97-Lys118) L1

(Phe43-Lys56) L4 a

(Tyr146-Gly153) L1

(Phe46-Lys50) L2 a
a L1

denotes 1 SDA label on the peptide, L2, 2 SDA labels and L4, 4 SDA labels.
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Figure A2. Mechanism of crosslinking using succinimidyl 4,4’- azipentanoate (NHS-diazirine; SDA).
In the first step (A), the protein is incubated with SDA which results in derivatization of primary
amine containing side-chains. In the second step (B), the SDA-labeled protein is exposed to UV
light (365 nm) and forms a reactive carbene intermediate with the loss of N2. The carbene forms
covalent adducts with reactants (R) within the distance of the spacer arm (R = water, formulation
additives or protein).
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Figure A3. Comparison of (A) photolabeling and (B) photocrosslinking methods. In photolabeling,
the protein is exposed to UV irradiation (365nm) in the presence of a photoactive reagent in the
excipient matrix. In photocrosslinking, a protein derivatized with a bifunctional photoactive reagent
is exposed to UV light (365 nm) in the presence of other matrix components (e.g. water, formulation
additives or protein), which produces crosslinked molecules.
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Figure A4. Second derivative amide I FTIR spectra of Mb-SDA (solid line) and unlabeled Mb
(dashed line) Mb in formulations (A) Mb alone (control), (B) Mb with raffinose and (C) Mb with Gdn
HCl. The band intensity (1650-1655 cm-1) observed for A and B indicates the presence of α-helix
in Mb, whereas the band intensity (~1630 and ~1670 cm-1) for (C) is mainly from the beta sheet
content.
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Table A4. List of all possible peptide-water adducts that can be formed by crosslinking with SDA.
A maximum of 4 SDA labels per peptide (and hence up to 4 H2O and 4 raffinose molecules per
peptide) were considered. The same list was considered for all possible peptide-raffinose adducts.
Peptide + 1SDA – 1N2

Peptide + 2SDA – 1N2

Peptide + 3SDA – 1N2

Peptide + 4SDA –

+ 1H2O

+ 1H2O

+ 1H2O

1N2 + 1H2O

Peptide + 2SDA – 2N2

Peptide + 3SDA – 2N2

Peptide + 4SDA –

+ 1H2O

+ 1H2O

2N2 + 1H2O

Peptide + 1SDA – 2N2

Peptide + 3SDA – 2N2

Peptide + 4SDA –

+ 2H2O

+ 2H2O

2N2 + 2H2O

Peptide + 3SDA – 3N2

Peptide + 4SDA –

+ 1H2O

3N2 + 1H2O

Peptide + 3SDA – 3N2

Peptide + 4SDA –

+ 2H2O

3N2 + 2H2O

Peptide + 3SDA – 3N2

Peptide + 4SDA –

+ 3H2O

3N2 + 3H2O
Peptide + 4SDA –
4N2 + 1H2O
Peptide + 4SDA –
4N2 + 2H2O
Peptide + 4SDA –
4N2 + 3H2O
Peptide + 4SDA –
4N2 + 4H2O
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N
A
B

(52 - 57)

D

(60 - 78)

E

(83 - 96)

F

(101 - 118)

G

(125 - 149)

C

H

C

Tryptic
Peptides
1 - 16
17 - 31
32 - 42
32 - 45
32 - 47
43 - 45
43 - 47
43 - 50
43 - 56
46 - 50
46 - 56
46 - 62
48 - 56
51 - 56
51 - 62
51 - 63
57 - 62
57 - 63
63-77/64-78 *
78 - 79
78 - 87
79 - 87
79 - 96
80 - 87
80 - 96
88 - 98
97 - 102
97 - 118
99 - 118
103 - 118
119 - 133
119 - 139
134 - 139
134 - 145
134 - 147
140 - 145
140 - 147
140 - 153
146 - 153
148 - 153
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Figure A5. Peptide-peptide adducts formed in (A) Mb-SDA alone (control), (B) Mb-SDA with
raffinose and (C) Mb-SDA with Gdn HCl lyophilized formulations. Peptide-peptide adducts formed
by maximum one (■), two (■), three (■) and four (■) SDA molecules from a single sample injection
are plotted. The

-helices from N-terminus to C-terminus in Mb are represented by cylinders


labeled A to H respectively.
* The molecular mass of tryptic fragments 63-77 and 64-78 are identical and cannot be
differentiated.
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C
Figure A6. Tryptic peptides of Mb detected as peptide-water adducts in (A) Mb-SDA alone (control),
(B) Mb-SDA with raffinose, (C) Mb-SDA with Gdn HCl lyophilized formulations and (D) Tryptic
peptides of Mb detected as peptide-raffinose adducts in Mb-SDA with lyophilized raffinose
formulation. Peptide-water adducts formed by maximum one (■), two (■), three (■) and four (■)
molecules of water from a single sample injection are plotted. Peptide-raffinose adducts formed
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with maximum one molecule of raffinose are plotted in orange. The α-helices from N-terminus to
C-terminus in Mb are represented by cylinders labeled A to H respectively.
* The molecular mass of tryptic fragments 63-77 and 64-78; 63-78 and 64-79 are identical and
cannot be differentiated.
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Figure A7. Peptide-peptide adducts formed in (A) Mb-SDA control, (B) Mb-SDA with raffinose and
(C) Mb-SDA with Gdn HCl solution formulations. Peptide-peptide adducts detected in single (■),
duplicate (■) and triplicate (■) sample injection(s) are plotted. Adducts were mapped irrespective
of the number of SDA linkages (1-4 SDA). The

-helices from N-terminus to C-terminus in Mb are


represented by cylinders labeled A to H respectively. * The molecular mass of tryptic fragments 6377 and 64-78; 63-78 and 64-79 are identical and cannot be differentiated. The molecular mass for
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peptide-peptide adducts (32-45 x 43-47) and (32-47 x 43-45); (79-87 x 51-63) and (78-87 x 51-62);
(63-78 x 57-63) and (63-79 x 57-62) are identical and cannot be differentiated.
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Figure A8. Percent weight loss with time at 50 ˚C, 0 % RH for Mb-SDA alone (dotted line), MbSDA with raffinose (dashed line) and Mb-SDA with Gdn HCl (solid line).
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Figure A9. X-ray diffractograms of lyophilized excipient-free (Mb-A) and sucrose-containing (MbB) myoglobin formulations. Crystalline features were not observed for Mb-A lyophilized with (black
line) and without (blue line) controlled nucleation. Similar diffractograms were obtained for Mb-B
lyophilized with (red line) and without (green line) controlled nucleation.
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Figure A10. SEM images of excipient-free (Mb-A; panels A, B) and sucrose-containing (Mb-B;
panels C, D) lyophilized myoglobin formulations. Panels A, C: Formulations lyophilized with
controlled nucleation; Panels B, D: Formulations lyophilized without controlled nucleation. The top
and bottom of each image represents the top and bottom of the cake respectively. Scale bars are
set at 500 µm.
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Figure A11. Moisture sorption kinetics for excipient-free (Mb-A) myoglobin formulations lyophilized
with (black line) and without (blue line) controlled nucleation and sucrose-containing (Mb-B)
myoglobin formulations lyophilized with (red line) and without (green line) controlled nucleation.
Moisture sorption was measured at 43 % RH, 5 °C for 3 h.
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Figure A12. Fraction of protein labeled with photo-leucine for excipient-free (Mb-A) and sucrosecontaining (Mb-B) myoglobin formulations lyophilized without controlled nucleation with a fill volume
of 200 or 500 µL. All lyophilized formulations contained 100:1 molar ratio of pLeu to protein and
were irradiated for 40 min at 365 nm. The fraction was calculated using peak heights of labeled
protein on the extracted ion chromatogram (EIC) obtained by LC-MS. The bars show the mean (±
SD) of three LC-MS injections. The two fill volumes showed significantly different means using a
paired t-test (p < 0.05, GraphPad Prism).
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